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Abstract 
DNA polymerase iota (polι) is a member of the Y-family, polymerases which are key 
components in translesion synthesis (TLS). As part of the DNA damage response, TLS 
allows cells to bypass damaged template DNA. Each member of the Y-family is capable 
of accurately replicating across from certain lesions. All Y-family polymerases are 
recruited by ubiquitination of the DNA sliding clamp, PCNA, by direct interaction with 
PCNA and ubiquitin. The mechanism of polymerase choice is not well understood, nor are 
the interactions between Ub-PCNA and the TLS polymerases. We studied the structure of 
the complex between the interacting region of polι and Ub-PCNA. Polι appears to be unable 
to bind all three monomers of homotrimeric Ub-PCNA simultaneously, even in a heavily 
truncated form. The maximum complex ratio observed was two polymerases per Ub-
PCNA ring. This assembly ratio limit may give insight into switching of multiple 
polymerases at the PCNA platform in DNA damage response. 
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Summary for Lay Audience 
Accurate replication of DNA is a key biological process. Organisms have evolved 
complementary maintenance processes to maintain the integrity of genetic information, 
such as low-error replication machinery, damage repair mechanisms, and replacement 
mechanisms using templates. These all work together to keep the mutation rate low. 
Translesion synthesis (TLS) is one component of the damage-response process, but its role 
is different. TLS replication tolerates damaged DNA and allows replication to continue 
past lesions when repair processes cannot respond in time, at the risk of mutation. TLS 
must be kept inactive to avoid unnecessary mutations, but quickly activated at damaged 
sites. This is accomplished by modifying the major hub protein for replication processes, a 
ring-shaped trimeric protein called PCNA. A small marker protein called ubiquitin (Ub) is 
added to a specific site, which displaces the regular replication machinery and acts as a 
binding site for the TLS proteins. The structure of the complex between Ub-PCNA and 
TLS proteins is poorly understood. Each of the TLS polymerases handles different types 
of damage well, but all of them are called by adding ubiquitin to PCNA. DNA polymerase 
iota (polι), one of the TLS proteins, was chosen an example to investigate. After initial 
attempts at structure determination by crystallography failed, indirect methods of probing 
the complex were used. The stoichiometry of the complex was found to be limited to two 
small polι constructs per UbPCNA ring by multiple independent methods. Coarse structural 
determination was also attempted by small-angle X-ray scattering, with ambiguous results. 
Here we argue that the limited stoichiometry observed and the unusual organization of polι 
suggests that its role is that of a final attempt at lesion bypass when other TLS polymerases 
have failed. This is in line with the minimal effect of having knocked out polι in model 
organisms, and a reasonably safe role considering its high tendency to mutate and relatively 
small number of lesions it appears to handle compared to the major TLS polymerase.  
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1 Introduction 
1.1 DNA Damage 
 In a living cell, DNA is constantly exposed to diverse forms of damage from both 
external and internal sources. It is estimated that some form of DNA damage occurs over 
10,000 times per day, per cell. Further complicating matters, DNA damage may take many 
forms. These range in severity from the minor (abasic sites, adducts) to the potentially 
catastrophic (double stranded breaks). Abasic sites are points where the nitrogenous base 
has been removed while leaving the sugar-phosphate backbone intact, leaving an empty 
space across from an unpaired base. Adducts are chemical additions to a correct base. Some 
adducts are harmless and are added as part of genetic regulation, such as DNA methylation, 
but other adducts are random occurrences. These random occurrences, especially if the 
adducts are large or heavily distorting (such as the TT cyclobutane dimer caused by UV 
radiation) are harmful to the cell, potentially producing a permanent mutation. Even minor 
DNA damage can create distortions in the DNA double strand: the strand must twist and 
adjust to accommodate the altered bases. 
Cells have evolved a range of responses to DNA damage to maintain genome 
stability, most famously the myriad repair mechanisms and pathways that lead to apoptosis 
when the damage is too great. Many of these pathways are error-free. These responses are 
not, however, appropriate in all situations the cell may encounter. 
1.2 Translesion Synthesis 
Translesion synthesis (TLS), a DNA damage tolerance mechanism, is an important 
tool in the DNA damage response kit (Goodman and Woodgate, 2013). TLS fills a niche 
in between damage repair and apoptosis, occurring during DNA replication. Ordinary 
replicative polymerases (pols α, δ, and ε in humans) are characterized by high processivity, 
restrictive active sites, and 3’-5’ exonuclease activity. The narrow active sites reduce the 
probability of incorporating mismatched bases, and the exonuclease activity acts as 
proofreading by removing mismatched bases. These features of replicative polymerases 
are key to the high fidelity of replication but may also be a point of vulnerability for the 
cell with DNA damage.  
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DNA replication can be stalled at lesioned sites, which would be deadly to the cell 
if not resolved (Durando et al., 2013). As noted above, lesioned sites disrupt the normal 
shape of DNA bases and may distort the shape of the backbone strand around its site. These 
changes make it difficult for replicative polymerases to replicate across lesions. It becomes 
difficult to add a base across the lesion and increases the probability that the exonuclease 
activity will remove an added base. The polymerase stalls at this site, but the helicase at 
the replication fork decouples and continues to unwind the DNA. If the stalling is not 
resolved, the increasing tracts of ssDNA will lead to a stress response that will eventually 
activate apoptosis (Rodriguez et al., 2008). Error-free repair pathways tend to be slow and 
may not be able to rescue replication in time. For this reason, evolution has selected for the 
TLS pathway: a damage response that can act fast enough to rescue replication. TLS is 
initiated by monoubiquitination of the proliferating cell nuclear antigen (PCNA) and 
involves the displacement of the replicative polymerase and its replacement by a TLS 
polymerase. 
 
 
Figure 1.1 Translesion synthesis activation. Upon encountering a lesion, the replicative 
complex stalls at the damage site (a). Stalling activates a stress response culminating in 
ubiquitination of PCNA (b). Ubiquitination displaces the replicative polymerase and 
recruits the TLS polymerase (c) which can then replicate past the damaged site (d). 
TLS does come with risk: it is inherently error-prone and thus mutagenic (Yang et al., 
2018). Because of this danger, TLS must be tightly regulated (Ghosal and Chen, 2013). 
TLS has also been found to be improperly active in cancer cells (Gao et al., 2016; Mutter-
Rottmayer et al., 2016). The most prominent family of TLS polymerases is the Y-family 
(Vaisman and Woodgate, 2017). 
     a          b         c                          d 
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1.3 Y-family polymerases and Polι 
 Y-family polymerases resemble replicative polymerases but have key differences 
to permit lesion bypass. These enzymes have low fidelity, low processivity, and low 
catalytic efficiency when replicating across normal template DNA (Yang, 2014). The basic 
Y-family organization contains a structured N-terminal catalytic domain and an 
unstructured C-terminal regulatory domain. The catalytic domain is similar to the classical 
polymerase structure, with the right-hand organization of a palm, finger, and thumb 
domain. 
 
Figure 1.2 Diagram of the classic polymerase domain (left) and the same superimposed 
over a right hand for context (right). The finger domain (green) binds the incoming 
nucleotide while the thumb domain helps to position the DNA strand. The palm domain 
contains the active site. 
The domain is differentiated by a looser active site, lack of exonuclease activity, 
and the addition of a further domain known as the little finger (LF) domain. These 
differences lead to an improved ability to accommodate and replicate across damaged 
template DNA at the cost of fidelity. The C-terminal domain regulates the protein’s 
activity. Though largely unstructured, they contain interacting motifs to that localize the 
enzyme to ubiquitinated proliferating cell nuclear antigen (PCNA), the eukaryotic. The two 
most important types of interacting motifs are the PCNA-interacting peptide (PIP or PIP 
box) (Haracska et al., 2005) and motifs for binding ubiquitin. The PIP-box of Y-family 
polymerases are non-canonical (Haracska et al., 2005) and have less affinity for PCNA 
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relative to replicative polymerases. There are two classes of motifs for ubiquitin binding: 
the ubiquitin binding zinc finger (UBZ) and the ubiquitin-binding motif (UBM). Together, 
these binding motifs lead to strong affinity for Ub-PCNA but poor affinity to PCNA in 
general. This keeps Y-family activity at a minimum under normal conditions but rapidly 
recruits them to stalled replication forks after PCNA ubiquitination. Y-family polymerases 
are themselves able to be ubiquitinated, and it is hypothesized that this ubiquitination 
prevents them from activating by keeping them in a self-binding conformation to preclude 
them from binding to Ub-PCNA (McIntyre et al., 2013). 
 
 There are four members of the Y-family polymerases, each with different activities. 
 
Figure 1.3 Comparison of Y-family polymerases. N-terminal catalytic domain 
organization is conserved across all members of the family, with classic polymerase core 
in red and the little finger domain in red. The C-terminal regulatory domain shows 
significant differences in composition and organization (adapted from Yang and 
Woodgate, 2007). 
 Each polymerase displays different catalytic properties and play unique 
roles. Rev1 is an unusual case: its catalytic activity is limited to adding dC across from any 
template, and it itself serves as a scaffold protein for further responses. Polη is the best 
studied member of the family. Humans lacking polη activity are afflicted with a variant of 
xeroderma pigmentosum (XPV), a skin disease which is characterized by high sensitivity 
to UV light. This is caused by losing polη’s ability to bypass TT cyclobutane dimers 
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quickly and accurately (Masutani et al., 1999), which is a function that other TLS 
polymerases lack. Polη also has a role in promoting monoubiquitination of PCNA at K164 
(Durando et al., 2013). Polκ’s primary function is strand extension following lesion bypass 
(Jha and Ling, 2018; Lone et al., 2007), but it is also capable of bypassing lesions on its 
own. Polι’s role in TLS is poorly understood. Its activity largely overlaps with that of polη, 
and likely functions as a backup or complement polymerase, such as its activity in XPV 
organisms (Wang et al., 2007) and its accurate bypass of 8-oxo-guanine lesions (Kirouac 
and Ling, 2011). One of its notable qualities is its unusual mutation spectrum: polι 
replicates inaccurately over a template T and favours misincorporation of dC over dA by a 
factor of 3:1. Despite its inaccuracy, polι has been shown to play a role in maintaining 
genetic integrity (Iguchi et al., 2014). The structure of its catalytic domain (PDB code: 
1T3N) has been solved in complex with various substrates (Nair et al., 2004).  
Pol follows the basic Y-family organization, and its regulatory domain contains a 
PIP-box and two UBMs. The UBM binds to ubiquitin in an unorthodox manner and does 
not bind to the typical isoleucine-44, rather the nearby isoleucine-8 (Bomar et al., 2010). 
The binding is also stabilized by electrostatic contacts (Burschowsky et al., 2011). 
Polι is a useful model for studying the Y-family polymerase family’s behaviour in 
vitro. Full-length Y-family proteins tend to be difficult to overexpress and purify in 
significant quantities, but the catalytic domain and regulatory domain may be individually 
soluble. The PIP-box of polι is located between the two domains, so that proteins of each 
domain can be created which contain the PIP-box in its natural point in the structure. This 
permits independent study of the N-terminal and C-terminal domains in proper complex 
with its key binding partner and regulator, PCNA. 
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1.4 PCNA and the Regulation of TLS 
 Human proliferating cell nuclear antigen (PCNA) is a key hub that physically 
bridges DNA and a multitude of proteins that act on DNA. PCNAs are the eukaryotic 
analogue to the bacterial β clamp. In humans, the protein naturally forms a ring-shaped 
homotrimer which can be loaded onto DNA and slide along the strand. The angle of the 
basic patches matches that of the backbone and contributes to the “cogwheel”-type sliding 
(De March et al., 2017). PCNA does not have enzymatic activity; rather it is a platform for 
a wide range of proteins.  
 
Figure 1.4 Diagram of the structure of PCNA. PCNA is a ring- shaped homotrimer. Each 
unit is composed of two similar domains, between which is a hydrophobic pocket and an 
unstructured region called the inter-domain connecting loop (IDCL, shown in black). The 
overall appearance is a ring with pseudo-sixfold rotational symmetry. The central pore is 
lined with basic residues which form weak interactions with the DNA backbone, permitting 
its sliding action (March and Biasio, 2017). 
The hydrophobic pocket and IDCL features form a binding site for the PIP box, which is a 
common binding motif in proteins which interact with DNA. The crystal structure of the 
polι PIP-box in complex with Ub-PCNA is known (Hishiki et al., 2009). The PIP binding 
site sits on the forward face of the ring, in the direction of the sliding. The angle of the 
basic patches matches that of the backbone and contributes to the “cogwheel”-type sliding 
(De March et al., 2017). PCNA does not have enzymatic activity; rather it is a platform for 
a wide range of proteins.  
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 In addition to the PIP-binding site, PCNA is subject to varied modifications to 
recruit specific proteins under specific circumstances. PCNA has been found to be 
SUMOylated, ISGylated, and ubiquitinated, all at multiple possible sites (Chen et al., 
2011). Each modification signals for different responses, so PCNA acts as both the 
interface between DNA and its proteins and the central point of regulation for many DNA-
related processes. 
 
Figure 1.5 Regulation of DNA damage responses by modification of human PCNA. 
Monoubiquitination of K164 is the signal that recruits translesion polymerases, including 
Y-family polymerases, to stalled replication forks to bypass lesions (adapted from Chen et 
al., 2011). 
 Stalled replication leads to monoubiquitination of PCNA at lysine-164 by RAD18, 
which activates the TLS response. This dislodges the replicative polymerase and recruits 
TLS polymerases, including polι. The exact mechanism is unknown, as is the structure of 
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the active TLS complex. All TLS enzymes are recruited by this same signal, which 
introduces a polymerase-selection problem: how can a cell ensure that a given lesion is 
bypassed by the most suitable polymerase? There are two competing models for this 
complex: the tool-belt model (Boehm et al., 2016) and the polymerase-switch model 
(Dovrat et al., 2014). 
 The tool-belt model is based on the homotrimeric structure of PCNA. Since PCNA 
(and Ub-PCNA) has threefold rotational symmetry, the system effectively contains 3 sets 
of identical binding sites. The active complex is hypothesized to be able to host a set of 
TLS polymerases (for example, pols η, ι, and κ) and rotate around the DNA to allow each 
polymerase to interrogate the lesion. In this way, the most suitable polymerase is the most 
likely to bypass the lesion and resolve the stalling. 
 The polymerase-switch model is not mutually exclusive with the tool-belt model, 
but it may occur without the creation of tool belts. In this model, only a single polymerase 
binds to Ub-PCNA at any time, requiring a complete detachment and new binding event to 
change the polymerase that is acting on DNA. Polymerases that bind to Ub-PCNA are 
themselves ubiquitinated while bound. Should the polymerase detach (a common 
occurrence since Y-family polymerases are distributive enzymes, with low processivity), 
it reverts to its self-binding closed conformation and is prevented from rebinding to Ub-
PCNA. Like the tool-belt model, this model resolves the polymerase-selection problem by 
decreasing the probability that the lesion will be bypassed by a polymerase which does not 
easily act upon the lesion. Though this is perfectly compatible with a tool-belt system (since 
there are more than three TLS polymerases, it would be necessary for that model to 
function), this model does not require in vivo tool belts to function and is compatible with 
a system using one bound polymerase at a time. 
1.5 Outline of Investigation 
 This project set out to investigate the structure of the complex between polι’s 
regulatory domain and Ub-PCNA. Determination of the crystal structure of the complex 
between Ub-PCNA and polι may offer clues about the mechanism of TLS and the 
behaviour of the lesion bypass complex. 
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Separate proteins of polι and (Ub-)PCNA and fusion proteins of two proteins had 
been developed for crystallization trials. After crystallization trials were exhausted, the 
unfused complex was examined to determine whether the complex was forming as 
hypothesized. Initial findings in multiangle light scattering experiments, followed by 
analytical ultracentrifugation and small-angle X-ray scattering studies, showed that the 
complex composition was not the expected 3:1 polymerase:trimer. Instead, the highest 
stoichiometry ever observed was 2:1 polymerase:trimer. Small-angle X-ray scattering 
experiments were performed to create a low-resolution structure in solution. 
2 Materials and Methods 
 The following lists of materials were used in experiments. In certain procedures the 
standard buffer may not be used; in this case the modification may be noted in the section 
describing the method in question. 
2.1 Bacterial strains and plasmids 
 Escherichia coli was the organism of choice for cloning procedures and protein 
production. The following strains were used in this project. 
Table 2.1 List of bacterial strains used in the study. 
Strain Name Use Key Features 
BL21-DE3 
Protein 
Production 
Protease deficient, primary protein production 
strain (Novagen) 
BL21-DE3 
(pRARE) 
Protein 
Production 
Protease deficient, pRARE plasmid requires 
chloramphenicol selection (Novagen) 
DH5α Cloning 
High transformation efficiency 
(Thermo Fisher Scientific) 
 
 The following plasmids were used as vectors for protein expression. Each plasmid 
is IPTG-inducible, encoded an N-terminal solubility tag and contained an antibiotic 
resistance for selection. The solubility tag is cleavable by TEV protease. The exception to 
the tagging system is the pET3a plasmid, which encodes a C-terminal 6xHis tag which is 
not cleavable. This vector was used for a single ubiquitination enzyme. 
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The pRARE plasmid was not transformed into bacteria at the same time as the vector 
plasmid; rather it was included in the competent cells. The plasmid encodes tRNAs that are 
rarely used in E. coli but common in other organisms. The extra tRNAs produced help to 
increase protein yield by removing the scarcity as a bottleneck. It is included on this list 
for the sake of completeness and to note the antibiotic required to select for its inclusion. 
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2.2 List of Standard Buffers 
Each buffer listed with its formulation and its main use. In cases where an experimental 
protocol uses a modified buffer, the modification is listed in its Methods section. 
Table 2.2 Standard buffers used in the study.  
Buffer Name Use Components 
His-Binding Buffer 
Ni Affinity 
Chromatography 
50 mM Tris pH 7.5, 500 mM NaCl, 5% 
glycerol (v/v) 
MBP-Binding 
Buffer 
Amylose Affinity 
Chromatography 
20 mM Tris pH 7.5, 200 mM NaCl, 1 mM 
EDTA 
Dialysis Buffer 
Overnight 
removal of 
imidazole 
25 mM Tris pH 7.5, 200 mM NaCl, 5% 
glycerol (v/v) 
Tandem Loading 
Buffer 
1-step 2nd Ni 
affinity and Q 
column loading 
25 mM Tris pH 7.5, 150 mM NaCl, 5% 
glycerol (v/v) 
Q Buffer A 
Anion Exchange 
Chromatography 
25 mM Tris pH 7.5, 2.5% Glycerol, 1 mM 
EDTA 
Q Buffer B 
Anion Exchange 
Chromatography 
25 mM Tris pH 7.5, 1 M NaCl, 2.5% glycerol 
(v/v), 1 mM EDTA 
Heparin Buffer C 
Heparin Affinity 
Chromatography 
50 mM sodium acetate (NaAc) pH 5.5, 5% 
glycerol 
Heparin Buffer D 
Heparin Affinity 
Chromatography 
50 mM NaAc pH 5.5, 1 M NaCl, 5% glycerol 
(v/v) 
Sizing Buffer 
Standard 
Experimental 
Buffer 
20 mM Tris pH 7.5, 150 mM NaCl 
SAXS Buffer 
SEC-SAXS 
running buffer 
20 mM Tris pH 7.5, 150 mM NaCl, 2.5% 
glycerol (v/v) 
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2.4 Expression and purification 
 The protein complex of interest is composed of UbPCNA and polι. UbPCNA is 
created by enzymatically ubiquitinating purified PCNA in vitro. Full-length polι cannot 
be expressed in soluble form, so truncated forms of the C-terminal were created. Fusion 
proteins featuring linked PCNA and polι were also created for crystallization purposes. 
 
Figure 2.1 Schematic of polι proteins used in study. Segments of the polι C-terminal region 
(green) were expressed and purified, both as individual proteins and as fusion constructs 
with PCNA (blue). Fusion constructs are connected by flexible linkers. The PIP-UBM1 
protein is the narrowest segment of polι used, including the PIP box (yellow) and UBM1 
(orange). The LF constructs include the little finger (LF) domain at the N-terminal. PIP-
UBM1-UBM2 constructs include the full C-terminal domain and all interacting regions of 
interest. 
2.4.1 PIPUBM1-PCNA Fusion Protein Purification 
Fusion proteins were developed to express the polι-PCNA complex as a single unit 
to eliminate the need for excess PIP-UBM1 to saturate the PCNA ring and to simplify the 
production process. The C-terminus of the PIP-UBM1 protein was fused to the N-terminus 
of PCNA by a flexible linker. The linker must be flexible and long enough to permit the 
desired interactions. It must also be polar to stabilize solvent interactions (Chen et al., 
2013). 
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Table 2.3 Polι-PCNA fusion proteins used in this study. 
Protein Name Description 
PIP-UBM1-PCNA 
Fusion between polι 415-530 and PCNA N-terminus, linked 
by a 24aa flexible linker. Purified using TEV-cleavable N-
terminal His-Mocr tag. 
PIP-del26-PIP-PCNA 
Fusion between polι 415-530 ΔK439-464 and PCNA N-
terminus, linked by a 24aa flexible linker. Purified using TEV-
cleavable N-terminal His-Mocr tag. 
PIP-del36-PIP-PCNA 
Fusion between polι 415-530 ΔK439-474 and PCNA N-
terminus, linked by a 24aa flexible linker. Purified using TEV-
cleavable N-terminal His-Mocr tag. 
PIP-del46-PIP-PCNA 
Fusion between polι 415-530 ΔK439-474, ΔK484-493 and 
PCNA N-terminus, linked by a 24aa flexible linker. Purified 
using TEV-cleavable N-terminal His-Mocr tag. 
LF-PIP-UBM1-PCNA 
Fusion between polι 415-530 and PCNA N-terminus, linked 
by a 24aa flexible linker. Purified using TEV-cleavable N-
terminal His-Mocr tag. 
StrpII-PIP-UBM1-
PCNA 
Fusion between polι 415-530 and PCNA N-terminus, linked 
by a 24aa flexible linker. Purified using TEV-cleavable N-
terminal His-Mocr tag. Strep-II tag is inserted after the tag 
such that it is the N-terminal of the cleaved protein 
StrpII- PIP-del26-PIP-
PCNA 
Fusion between polι 415-530 ΔK439-464 and PCNA N-
terminus, linked by a 24aa flexible linker. Purified using TEV-
cleavable N-terminal His-Mocr tag. Strep-II tag is inserted 
after the tag such that it is the N-terminal of the cleaved protein 
StrpII- PIP-del36-PIP-
PCNA 
Fusion between polι 415-530 ΔK439-474 and PCNA N-
terminus, linked by a 24aa flexible linker. Purified using TEV-
cleavable N-terminal His-Mocr tag. Strep-II tag is inserted 
after the tag such that it is the N-terminal of the cleaved protein 
StrpII- PIP-del46-PIP-
PCNA 
Fusion between polι 415-530 ΔK439-474, ΔK484-493 and 
PCNA N-terminus, linked by a 24aa flexible linker. Purified 
using TEV-cleavable N-terminal His-Mocr tag. Strep-II tag is 
inserted after the tag such that it is the N-terminal of the 
cleaved protein 
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Fusion proteins were developed to express the polι-PCNA complex as a single unit 
to eliminate the need for excess PIP-UBM1 to saturate the PCNA ring and to simplify the 
production process. The C-terminus of the PIP-UBM1 protein was fused to the N-terminus 
of PCNA by a flexible linker (see Figure 2.1). The linker must be flexible and long enough 
to permit the desired interactions. It must also be polar to stabilize solvent interactions 
(Chen et al., 2013). 
The StrpII tag (Schmidt and Skerra, 2007), originally designed as an affinity tag, 
was added to the N-terminal of the cleaved protein. The tag was originally considered to 
stabilize the N-terminus of the protein and eliminate a possible degradation product, but it 
was ultimately included to alter the crystallization behaviour and open a new round of 
screening (Lukat et al., 2008) 
All fusion proteins were expressed in E. coli BL21 (DE3) cells. Cells are grown in 
lysogeny broth (LB) + Ampicillin (100 mg/L) at 37 ºC to OD600= 0.6 and then induced 
with 0.5 mM IPTG. PIP-UBM1 fusions are expressed at 37 ºC and harvested 4 hours after 
induction. LF-PIP-UBM1 fusions are expressed at 16 ºC and grown overnight before 
harvest. Cells are pelleted and stored frozen at -80ºC. 
 Cell pellet from 1 L culture was thawed in a room temperature water bath at use 
and resuspended in a lysis buffer made from His-binding buffer with 1 mM benzamidine, 
1 mM PMSF, and 5 mM BME. Cells were lysed using a homogenizer and the crude lysate 
was centrifuged at 20,000 rpm (approximately 40,000 g) for 30 minutes. The supernatant 
was poured off and loaded on a 5mL Roche His cOmplete Ni column. The column was 
washed with 50mL His-binding buffer, 50mL of His-binding buffer adjusted to 1 M NaCl, 
50 mL His-binding buffer, and finally 50 mL of His-binding buffer with 10 mM imidazole. 
The column was then eluted using His-binding buffer with 500 mM imidazole into 12x1.5 
mL fractions. Fractions were pooled based on spot test and TEV protease was added at a 
ratio of 1 mg for every 30 mg of protein in the pooled fractions. The pooled sample was 
dialyzed against 150mM NaCl, 25 mM Tris pH 7.5, and 5% glycerol at 4 ºC overnight. 
 The digested sample was retrieved the next morning and loaded onto a tandemly 
connected Roche nickel column flowing into a 5 mL GE HiTrap Q column equilibrated to 
150 mM NaCl. The digested sample was pushed through the column with additional buffer 
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and the Q column was removed, then connected to an AKTA Purifier for elution. The 
protein was eluted using a gradient of 15-70% buffer B over 7.5 CV and collected in 1.5 
mL fractions based on UV absorbance. A contaminant band produced a pronounced 
shoulder in the peak, but the contaminant could be reasonably eliminated by pooling early 
fractions only. The early fractions were pooled and concentrated to 10mg/mL and were 
used to set up crystallization trays. 
2.4.2 polι C-terminal Protein Purifications 
Note on buffers: PIP-UBM1 proteins are purified in standard buffers at pH 8.7 to 
allow binding to Q column. Q buffer B contains 500 mM NaCl to make low-salt buffers 
more accurately. 
E. coli  BL21 (DE3) cells expressing 8xHis-PCNA were grown in LB + Ampicillin 
(100 mg/L) to OD600 = 0.7 at 37 ºC and induced with 0.5 mM imidazole. Cells were grown 
a further four hours at 37 ºC before harvest. Cell pellets were stored at -80 ºC. 
Table 2.4 Polι C-terminal proteins used in the study. 
Protein Name Description 
PIP-UBM1 
Main polι C-terminal protein, containing aa 415-530. Purified using 
TEV-cleavable N-terminal HisMocr or HisMBP tags. 
PIP-UBM1 del 26 
Truncated polι C-terminal protein, containing aa 415-530 ΔK439-
464. Purified using TEV-cleavable N-terminal HisMocr or 
HisMBP tags. 
PIP-UBM1 del 36 
Truncated polι C-terminal protein, containing aa 415-530 ΔK439-
474. Purified using TEV-cleavable N-terminal HisMocr or 
HisMBP tags. 
LF-PIP-UBM1 
polι C-terminal protein with little finger polymerase domain (LF), 
containing aa 415-530. Purified using TEV-cleavable N-terminal 
HisMocr or HisMBP tags. 
PIP-UBM1-
UBM2 
Full polι C-terminal protein, containing aa 415-715. Purified using 
TEV-cleavable N-terminal HisMocr or HisMBP tags. 
Cell pellet from 1 L culture was thawed in a room temperature water bath at use 
and resuspended in a lysis buffer made from His-binding buffer with 1 mM benzamidine, 
1 mM PMSF, and 5 mM BME. Cells were lysed using a homogenizer and the crude lysate 
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was centrifuged at 20,000rpm for 30 minutes. The supernatant was then loaded on a 5mL 
Roche His cOmplete Ni column.  
The Ni column was washed with 150 mL of His-binding buffer and then eluted into 
12x1.5 mL fractions using His-binding buffer with 500 mM imidazole. Fractions were 
pooled based on spot test and TEV protease was added at a ratio of 1 mg for every 20 mg 
of protein and dialyzed overnight against 20 mM Tris-HCl pH 8.7, 200 mM imidazole, 
2.5% glycerol, and 5mM BME. 
The digested protein was retrieved the next morning and diluted 6x in buffer A. The 
diluted protein was loaded on a 5mL HiTrap Q column equilibrated in 6% buffer B (30 
mM NaCl). The protein was eluted on an AKTA Purifier from the column using a gradient 
of 6%-50% over 6 column volumes and collected in 1.5 mL fractions based on UV 
absorbance. Protein was concentrated to 15 mg/mL, spiked to 20% glycerol (v/v), and flash 
frozen before storage at -80 ºC. 
2.4.3 PCNA Purification – Primary Method using His-tagged protein 
E. coli  BL21 (DE3) cells expressing 8xHis-PCNA were grown in LB + Ampicillin 
(100 mg/L) to OD600 = 0.7 at 37 ºC and induced with 0.5mM imidazole. Cells were grown 
a further three hours at 37 ºC before harvest. Cell pellets were stored at -80 ºC. 
Cell pellet from 1 L culture was thawed in a room temperature water bath at use 
and resuspended in a lysis buffer made from His-binding buffer with 1 mM benzamidine, 
1 mM PMSF, and 5 mM BME. Cells were lysed using a homogenizer and the crude lysate 
was centrifuged at 20,000rpm for 30 minutes. The supernatant was then loaded on a 10mL 
Roche His cOmplete Ni column. 
The column was then eluted using His-binding buffer with 500 mM imidazole into 
16x1.5 mL fractions. Fractions were pooled based on spot test and TEV protease was added 
at a ratio of 1 mg for every 40 mg of protein in the pooled fractions. The pooled sample 
was dialyzed against 200 mM NaCl, 25 mM Tris pH 7.5, and 5% glycerol at 4ºC overnight. 
Protein sample was retrieved the next morning and spiked to 500mM NaCl. The 
sample was passed through His cOmplete column again and the flowthrough collected. 
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Flowthrough was diluted with Q buffer A to 150 mM NaCl and loaded on 10 mL Q column 
pre-equilibrated in 15% B. Column was eluted using a gradient of 15-70% B over 7.5 CV 
and collected in 1.5 mL fractions based on UV absorbance. Peak fractions were pooled and 
concentrated to roughly 10 mg/mL, spiked to 20% glycerol and flash-frozen before storage 
at -80 ºC. 
2.4.4 PCNA purification – Method for untagged PCNA 
 Untagged PCNA was at first the only PCNA protein available, before HisPCNA 
that was TEV-cleavable was designed. A small number of standard PCNA purifications 
were performed using this method. The main use of this purification was to produce lysine 
to arginine (K/R) mutant PCNA for ubiquitination tests (outlined below). 
Table 2.5 Untagged PCNA proteins purified by ion exchange/heparin affinity method. 
Protein Name Description 
PCNA Human PCNA, untagged 
PCNA K164R Untagged human PCNA with K164R point mutation 
PCNA K168R Untagged human PCNA with K168R point mutation 
PCNA K164/168R 
Untagged human PCNA with K164/168R point 
mutations 
 
E. coli  BL21 (DE3) cells expressing human ubiquitin (Ub) were grown in LB + 
Ampicillin (100 mg/L) at 37 ºC to OD600 = 0.7 and then induced with 0.5mM IPTG. After 
induction cells were incubated at 37ºC for 3 hours and harvested (normal yield 3.5-4 g/L), 
and the cell pellets were stored at -80ºC. 
Purification began by thawing 1 L worth of cells (3.5-4 g) and suspending in 15% 
Buffer B with 5 mM BME, 0.01% (v/v) NP-40, and 1 mM each benzamidine and PMSF. 
The suspended cells were then lysed using a homogenizer. The lysate was spun down at 
20,000 rpm for 30 minutes at 4 ºC. The supernatant was poured off and then loaded on a 
pre-equilibrated Q column. The Q column was then connected to the purifier and eluted 
using a 15-25% gradient over 10 mL, followed by 25-70% over 40mL. The initial slow 
gradient removes a strong band of protein and DNA immediately before the elution of the 
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PCNA. Fractions with a conductivity between 20 mS and 40 mS were examined by SDS-
PAGE and relatively clean fractions were pooled and dialyzed overnight against 10% 
buffer D to prepare for heparin chromatography the next day. 
Protein was loaded on a pre-equilibrated heparin column and then connected to the 
purifier. The column was eluted using a 10-50% gradient over 40 mL. Peak fractions were 
pooled and diluted back to 10% D for reloading. The reloaded protein was then eluted using 
a 10-70% gradient and peak fractions were concentrated for storage, typically 10 mg/mL. 
Protein was flash frozen and stored at -80 ºC. 
2.4.5 Ubiquitin Purification 
 E. coli  BL21 (DE3) cells expressing human ubiquitin (Ub) were grown in LB + 
Ampicillin (100 mg/L) at 37 ºC to OD600 = 0.7 and then induced with 0.5mM IPTG. After 
induction cells were incubated at 30ºC overnight and harvested, and the cell pellets were 
stored at -80ºC. 
 Full scale purification requires 4 L worth of cells to begin. Cells were thawed using 
a room-temperature water bath and resuspended in Buffer A (50mM NaAc pH 4.5, 1mM 
EDTA) and lysed using a homogenizer. The lysate was spun down at 20,000 rpm for 30 
min at 4 ºC. The supernatant was collected and heated in a water bath set to 75ºC for 30 
minutes. The sample was shaken every 3 minutes during this period to heat evenly. The 
heat-treated sample was then centrifuged as above, and the supernatant was collected. The 
supernatant was collected, and its pH was brought to 7.5 using 1M Tris-HCl pH 8 and 
loaded on a 10mL Q column equilibrated in 5% buffer A and the flowthrough collected. 
The Q column was cleared using 2M NaCl and the collected flowthrough was reloaded 
onto the column. This second flowthrough was collected and concentrated using a pressure-
powered concentrator to 10mL and then concentrated to 19mg/mL using a centrifugal 
concentrator. The protein was aliquoted and flash-frozen before storage at -80 ºC. 
2.4.6 hUba1 Purification 
 E. coli  BL21 (DE3) cells expressing His-hUba1 were grown in LB + Ampicillin 
(100 mg/L) at 37 ºC to OD600 = 0.7, and then induced with 0.25 mM IPTG. Cells were then 
grown overnight at 16 ºC and then harvested. Cell pellets were stored at -80 ºC. 
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 Cells from 2 L of culture were thawed and resuspended in His-binding buffer with 
benzamidine and PMSF. Cells were lysed on homogenizer and spun down at 20,000 rpm. 
The supernatant was loaded on a 10 mL Roche His cOmplete Ni column and washed with 
200 mL buffer and 100 mL buffer with 10 mM imidazole. The protein was eluted into 
16x1.5 mL fractions with His-binding buffer + 500 mM imidazole. The fractions 
containing protein were pooled and diluted 10x in Q buffer A to 50 mM NaCl and loaded 
onto a 10 mL Q column. The Q column was eluted on an AKTA Purifier using a gradient 
of 5%-50% over 10 CV and collected in 1.5 mL fractions based on UV absorbance. Peak 
fractions were pooled and concentrated to 3.8 mg/mL. Aliquoted protein and flash-froze 
before storing at -80 ºC. 
2.4.7 hUbC S22R Purification 
 E. coli  BL21 (DE3-pRARE) cells expressing His-hUba1 S22R were grown in LB 
+ Kanamycin (50 mg/L) + Chloromphenicol (34 mg/L) at 37 ºC to OD600 = 0.7 and then 
induced with 0.5 mM IPTG. Cells were grown at 16ºC overnight and harvested. Cell pellets 
were stored at -80ºC. 
 Cells from 2 L of culture were thawed and resuspended in His-binding buffer with 
benzamidine and PMSF and then lysed on a homogenizer. The lysed cells were centrifuged 
at 20,000 rpm for 30 minutes and the supernatant was then loaded onto a 10 mL Roche His 
cOmplete Ni column. The column was then washed with 100 mL His-binding buffer, 
followed by 50 mL of His-binding buffer with 10 mM imidazole. The protein was eluted 
into 16x1.5 mL fractions with His-binding buffer with 300 mM imidazole. Fractions with 
protein were pooled and digested with 1 mg TEV protease for every 20 mg protein while 
dialyzing against 25 mM Tris pH 7.5, 200 mM NaCl and 5% glycerol overnight. The next 
morning the digested protein was spiked to 500 mM NaCl and 10 mM MgCl2 before being 
loaded on a 10 mL Ni column. The flowthrough was collected and concentrated to 17.2 
mg/mL, flash frozen, and stored at -80 ºC. 
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2.5 Ubiquitination of PCNA 
2.5.1 Ubiquitination Reaction Conditions 
Reliable, site-specific monoubiquitination of PCNA at K164 was necessary for the 
study. The PCNA ubiquitination reaction was performed under the following conditions in 
aqueous buffer, modified from a previously published condition (Hibbert and Sixma, 
2012). A typical ubiquitination reaction has a PCNA concentration of ~0.5 mg/mL. As a 
matter of good practice, protein concentrations were re-evaluated after new stocks of Uba1, 
UbC, and/or ubiquitin were prepared. 
Table 2.6 Ubiquitination reaction conditions.  
Component Concentration 
MMT Buffer 10x pH 9 1x 
NaCl 25 mM 
MgCl2 3 mM 
TCEP 0.5 mM 
ATP pH 7 3 mM 
PCNA 16 μM 
Ubiquitin 22 μM 
Uba1 40 nM 
UbC S22R 16 μM 
 
Note: MMT 10x buffer is a broad-range buffer mixture that is 200 mM malic acid, 400 mM 
MES, and 400 mM Tris. 
The final reaction buffer volume was calculated from the total mass of PCNA to be 
ubiquitinated. All non-protein components were mixed first at room temperature, and then 
each protein was added individually with mixings in between. The final component added 
was hUbiquitin. The reaction mixture was incubated in a water bath at 37 ºC for 80 minutes, 
with gentle mixing performed every 20 minutes. At the end of the reaction time, the 
reaction mixture was loaded on an appropriately sized HiTrap Q column pre-equilibrated 
with 15% Buffer B and washed with 2 CV of the equilibration buffer. The column was then 
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eluted on an AKTA Purifier using a gradient of 15%-70% over 4 CV and collected in 1.5 
mL fractions based on UV absorbance. 
2.5.2 Confirmation of ubiquitination specificity by Mass Spectrometry 
 Polι specifically binds to PCNA ubiquitinated at lysine-164 (K164), so it was 
important to confirm that the ubiquitination reaction used was only ubiquitinating at this 
specific residue. Mass spectrometry was used to determine the ubiquitination site(s) present 
(Parker et al., 2009). 
 Freshly ubiquitinated Ub-PCNA from a small-scale ubiquitination was run on an 
SDS-PAGE gel. The ubiquitination reaction was run for two hours rather than the usual 80 
minutes to improve the chances of multiple ubiquitinations. A gel was run using multiple 
concentrations of the same sample across all the lanes to provide options for resolution vs. 
sample size. Spots were cut from the gel using a robotic sampler and submitted for trypsin 
digestion. The peptide products of the digest were submitted for MALDI-TOF to measure 
the masses of the fragments. 
 
 
Figure 2.2 Workflow for ubiquitination site determination by mass spectrometry. 
Ubiquitinated protein (a) is digested in-gel to peptides (b), including a small GG isopeptide 
scar on the ubiquitination site(s). The masses of the peptides are determined by MALDI-
TOF mass spectrometry (c). 
Observed peptides were compared to a generated library of possible tryptic 
digestion products (including possible missed cutting sites, oxidation products, and non-
a          b         c 
22 
 
specific modifications) from Ub-PCNA to identify fragments containing a mass shift of 
+129 Da from the normal mass, which corresponds to the GG scar from the ubiquitin-lysine 
isopeptide bond. Fragments marked with this scar are identified as ubiquitination sites. 
2.5.3 Confirmation of ubiquitination specificity using mutant PCNA 
 The specificity of the ubiquitination reaction was also tested by performing the 
normal ubiquitination reaction (see above) using K/R mutants of PCNA. Arginine is a 
positively charged amino acid with a long side chain like lysine, but it cannot be 
ubiquitinated like lysine (Hibbert and Sixma, 2012). Such mutations, properly placed, 
should abolish ubiquitination without affecting other properties of the protein. 
 Three PCNA mutants were generated by point mutation and purified using the 
untagged PCNA purification procedure: K164R, K168R, and K164/168R. K164 is the 
target site, and K168 was believed to be the most probable off-target site based on its 
proximity to the target site. A ubiquitination reaction was performed on each mutant and a 
wild-type control in parallel. The start and end points of the reaction were run on an SDS-
PAGE gel to determine which of the mutants were able to be ubiquitinated under these 
conditions. 
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2.6 Crystallization Trials 
 PIP-UBM1-PCNA fusion proteins were screened for possible crystallization 
conditions using the following kits: 
Table 2.7 Crystal screening kits used. 
Crystal Kit # of Wells Manufacturer Type 
PEG Smear 96 
Mixed in house, based on 
(Chaikuad et al., 2015) 
PEG mixtures, salts 
Wizard 1-4 192 Molecular Dimensions Broad Screen 
Natrix 1+2 96 Hampton (Scott et al., 1995) Salt mixture 
PEG 400 Ion 48 
Hampton (Mcpherson, 
2001) 
PEG 400 and salts 
PEG 550 
MME Ion 
48 Hampton 
PEG 550 monomethyl 
ether and salts 
PEG 1000 Ion 48 Hampton PEG 1000 and salts 
PEG 1500 Ion 48 Hampton PEG 1500 and salts 
PEG 2000 Ion 48 Hampton PEG 2000 and salts 
PEG 2000 
MME Ion 
48 Hampton 
PEG 2000 monomethyl 
ether and salts 
PEG 4000 Ion 48 Hampton PEG 4000 and salts 
PEG 5000 Ion 48 Hampton PEG 5000 and salts 
PEG 6000 Ion 48 Hampton PEG 6000 and salts 
Morpheus 96 
Molecular Dimensions 
(Gorrec, 2009) 
Broad, includes ligands, 
cryoprotective 
Index 96 
Hampton (D’Arcy et al., 
2003) 
Broad screen, diagnostic 
JCSG+ 96 
Molecular Dimensions 
(Newman et al., 2005) 
Broad 
MIDAS 96 Molecular Dimensions 
Narrow salt/pH, unusual 
polymeric precipitants 
Protein 
Complex 
96 Qiagen PEG and salt screen 
PACT Premier 96 
Molecular Dimensions 
(Newman et al., 2005) 
Screens pH, cations, and 
anions 
Crystal Screen 
1+2 
96 
Hampton (Jancarik and 
Kim, 1991) 
Broad 
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Fusion proteins were screened after concentrating ion exchange fractions, either 
from purification or after ion exchange refresh from storage at -80 ºC. Protein was 
concentrated to 10-15 mg/mL and diluted as needed before setting up trays. Trays were 
placed in incubators set to 18 ºC and observed over a few months for crystals using a 
microscope. 
Screening proceeded using 1+1 µL drops using protein concentrations of 5 or 10 
mg/mL. Two basic screening setups were used. First; hanging drop vapour diffusion 
experiments were set up in 24-well plates using a precipitant solution mixed in the drop 
and a well condition of 0.5 mL of 1M (NH4)2SO4 or 1.5M NaCl. Second; sitting drop 
experiments were performed using a well condition of 80 µL of the precipitating condition. 
2.7 Size-Exclusion Chromatography – Multi-Angle Light Scattering (SEC-MALS) 
2.7.1 Sample Preparation for SEC-MALS 
 Ub-PCNA and PIP-UBM1 were taken out of -80 ºC storage and thawed. Both 
proteins were refreshed by injecting on S200 equilibrated in sizing buffer + 0.5 mM DTT. 
Peak fractions of each were pooled to create high quality samples of sufficient 
concentration directly from the column. Mixtures were prepared a minimum of 30 minutes 
before injection to ensure equilibration of the mixture. 
2.7.2 Experimental Protocol 
 The SEC-MALS system was equilibrated in sizing buffer + 0.5 mM DTT (matching 
the buffer used to prepare samples). Once the sizing column was fully equilibrated, the 
flow into the MALS reference cell was stopped. 125 µL of sample was loaded into the 100 
µL loop to ensure that it was fully loaded. Injection was programmed to occur after 10 mL 
of buffer had flowed through the column since starting the program. MALS data were 
collected and processed in ASTRA (Wyatt Technologies). 
2.8 Analytical Ultracentrifugation 
2.8.1 Sample Preparation for Analytical Ultracentrifugation 
 Frozen samples of proteins to be run PIP-UBM1(-UBM2) and Ub-PCNA were 
thawed and individually injected into a GE S200 size exclusion column pre-equilibrated in 
sizing buffer with 0.5 mM DTT. Peak fractions were collected and pooled in order to 
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produce a sample of sufficient concentration directly from the sizing column. An additional 
aliquot of the sizing buffer was kept on ice for use in the reference cell. 
2.8.2 Analytical Ultracentrifugation Sedimentation Velocity Experiments 
 Sedimentation velocity experiments were performed to determine the stoichiometry 
of the complex between polι and Ub-PCNA by measuring the molecular weight of species 
in solution.  UV absorbance optics were used to track sedimentation velocity. 
 Stored samples of Ub-PCNA and of PIP-UBM1 (or PIP-UBM1-UBM2) were 
thawed and refreshed (as noted above) by size-exclusion chromatography using an GE 
Superdex S200 column pre-equilibrated in Sizing Buffer with 0.5 mM DTT, which also 
served to match the sample buffers. A 10 mL sample of the Sizing Buffer was kept separate 
for sample dilutions and reference cells. 0.5 mL fractions were collected based on UV 
absorbance. Peak fractions of each protein were pooled for a working concentration 
(Roughly 5 mg/mL each for PIP-UBM1 experiments, and roughly 2.5 mg/mL each for PIP-
UBM1-UBM2 experiments). 
 Experiments using PIP-UBM1 were performed using a wavelength of 293 nm to 
track Ub-PCNA only while leaving PIPUBM1 virtually invisible. Trimeric Ub-PCNA was 
kept to a constant concentration 18 μM while PIP-UBM1 ratios were varied between cells. 
Each individual experimental run included a Ub-PCNA standard cell to ensure reliability 
since the expected mass change is so small.  
 The sedimentation velocity experiments were run at 20 ºC over a period of 7.5 
hours, at a  radially mean force of 89,180 g. Scans of absorbance vs radial length were 
conducted at 10-minute intervals for a total of 45 scans. Cells depleted over the course of 
the experiment. 
Experiments using PIP-UBM1-UBM2 were performed using a wavelength of 280 
nm to match the standard protein UV absorbance peak. The aromatic amino acid content, 
and thus absorbance spectra, of Ub-PCNA and PIP-UBM1-UBM2 are similar, thus the 
strategy employed in PIP-UBM1 experiments could not be applied here. Ub-PCNA trimer 
concentration was kept constant in each cell, but at 4.5 μM to keep the absorbance low 
enough to also track PIP-UBM1-UBM2. Ub-PCNA-only absorbance under these 
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conditions was 0.5, which left room for higher ratios of PIP-UBM1-UBM2. The binding 
partner ratio was varied to determine the possible complex stoichiometries. 
 Sedimentation velocity data were analyzed in the SEDFIT program (Schuck, 2000) 
to produce a continuous c(s) distribution, with peaks corresponding to the observed 
sedimentation coefficient (sw) of the species in solution. This sedimentation coefficient can 
be used to estimate the molecular weight of the species in solution by the Svedberg 
relationship: 
𝑀
𝑁𝐴
=
𝑠𝑓
1 − ?̅?𝜌
 
Equation 1. The Svedberg relationship, where M is the molecular weight, NA is 
Avogadro’s number, s is the sedimentation coefficient, f is the frictional coefficient, ?̅? is 
the partial specific volume, and ρ is the solvent density. The solvent density and partial 
specific volume were calculated using SEDNTRP, a SEDFIT-suite program. 
Analysis proceeded using a single frictional coefficient for all runs to try to avoid 
biasing results. This coefficient was initially determined by fitting the Ub-PCNA standard 
estimate to its known molecular weight and applying the same coefficient to each of the 
remaining cells. The frictional coefficient is the relationship between the apparent size of 
the molecule and its resistance to sedimentation, i.e. between two molecules of identical 
molecular weight, the molecule with the smaller frictional ratio will sediment faster. This 
value may be floated during analysis but changing its value will cause species with identical 
sedimentation coefficient to have different apparent molecular weights. The frictional ratio 
is determined by the shape and flexibility of the species. Since the Ub-PCNA trimer forms 
the bulk of the PIPUMB1-Ub-PCNA complex, the frictional ratio of each complex should 
differ little from that of Ub-PCNA on its own. 
2.8.3 Analytical Ultracentrifugation Sedimentation Equilibrium Experiments 
 Sedimentation equilibrium experiments were performed to determine the 
dissociation constants of the polι-Ub-PCNA complexes. Sample preparation was 
performed in the same manner as the sedimentation velocity experiments. UV absorbance 
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optics were again used to track sedimentation. Experiments were performed using 2-cell 
centrepieces. 
 Experiments using PIP-UBM1 complexes were again performed using a 
wavelength of 293 nm to simplify the system and track Ub-PCNA alone. Ub-PCNA trimer 
concentration was held constant at 8.9 μM across all cells and three complexes were run: 
Ub-PCNA alone, 1:2 trimer:PIP and 1:4 trimer:PIP. Samples were mixed in a 175 µL 
volume, from which 150 µL were loaded into the sample cell. 175 µL buffer was loaded 
into the reference cell. 
 Equilibrium experiments with PIP-UBM1 and Ub-PCNA were performed at 20 ºC 
for a total of 87 hours. The PIP-UBM1 experiment was performed with the following 
speeds and timepoints. The remaining mixed sample was mixed with SDS sample and 
frozen so that an SDS-PAGE gel could be run to determine whether any degradation 
occurred. 
 Experiments using PIP-UBM1-UBM2 were performed using a wavelength of 280 
nm to maximize sensitivity. The absorbance spectra of PIP-UBM1-UBM2 and Ub-PCNA 
are similar and there is not a convenient wavelength to observe only Ub-PCNA. Ub-PCNA 
trimer concentration was held constant at 2.7 μM and three complexes were run: 1:0.8, 1:1, 
and 1:2 trimer:PIP. 
Equilibrium experiments with PIP-UBM1-UBM2 and Ub-PCNA were performed 
at 20 ºC for a total of 68 hours. The PIP-UBM1-UBM2 complex equilibrium experiment 
was performed with the following speeds and timepoints. 
Based on the results of the PIP-UBM1 complex experiments, the speeds and 
number of scans were reduced to improve the quality of the data. The experimental setup 
used does not accurately measure the concentration at A > 1.1, thus at higher speeds larger 
segments of each scan would be excluded from analysis. Since the most important part of 
a scan is the most concentrated section, excluding this end may lead to unreliable data. 
Data analysis of all SE experiments were performed using SEDPHAT’s multi-
speed equilibrium processing (Vistica et al., 2004). The analysis used a 3-site symmetric 
binding model and treated the entire Ub-PCNA trimer as the central binding partner with 
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three binding sites. This model was chosen because the observed particle is the Ub-PCNA 
trimer in addition to its bound partners. Unfortunately, this model is much more 
complicated than a standard heteroassociation A+B-type model. 
𝐾𝐷
𝐼 =
(𝐴 + 𝐴𝐵𝐼𝐼 + 𝐴𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐼𝐵𝐼𝐼𝐼) ∙ 𝐵
(𝐴𝐵𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼𝐵𝐼𝐼𝐼)
 
𝐾𝐷
𝐼𝐼 =
(𝐴 + 𝐴𝐵𝐼 + 𝐴𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼𝐼) ∙ 𝐵
(𝐴𝐵𝐼𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼 + 𝐴𝐵𝐼𝐼𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼𝐵𝐼𝐼𝐼)
 
𝐾𝐷
𝐼𝐼𝐼 =
(𝐴 + 𝐴𝐵𝐼 + 𝐴𝐵𝐼𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼) ∙ 𝐵
(𝐴𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐼𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐵𝐼𝐼𝐵𝐼𝐼𝐼)
 
Equation 2. KD equations in a three-site binding model. Each binding site is considered 
separately (ABI, ABII, and ABIII) and each individual KD accounts for all possible 
populations in equilibrium (9 in total). This model keeps all binding sites in saturation with 
one another, rather than saturating each binding site stepwise. 
2.9 Small-Angle X-ray Scattering Experiments (SAXS) 
2.9.1 Size-Exclusion Chromatography – Small Angle X-ray Scattering 
 SEC-SAXS experiments (Malaby et al., 2015) were performed at the Advanced 
Photon Source (APS) beamline 18D. Samples of Ub-PCNA and PIP-UBM1 were purified 
and concentrated in lab and shipped to APS. 250 µL samples of complex were prepared 30 
minutes prior to injection to allow for equilibration and then injected into a fast-flow S200 
gel filtration column pre-equilibrated in SAXS buffer at room temperature inside the 
beamline hutch. The beam wavelength was 1.54 Å. X-ray scattering images were collected 
before, across, and after the peak through an inline capillary. This experimental setup uses 
size exclusion chromatography to ensure that the sample is monodisperse (assuming good 
separation on the column) and the inline capillary combined with low exposure per frame 
reduces the effect of radiation damage on the sample collected. The capillary system is 
thoroughly cleaned using hydrophobic liquid to prevent buildup of damaged proteins and 
thus improve the quality of the data collected. 
 Basic SAXS processing was performed at the beamline using the RAW software 
suite. Molecular weight (MW) and radius of gyration (Rg) measurements are easily 
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processed and were used to assess the data quality. SAXS envelope modelling was 
performed using DAMMIN (Svergun, 1999), DAMMIF (Franke and Svergun, 2009), and 
GASBOR (Svergun et al., 2001). Visualization of the envelope was performed in PyMOL. 
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3 Results 
3.1 Purification of polι and (Ub)-PCNA proteins 
3.1.1 PIP-UBM1-PCNA fusion proteins can be separated from contaminants. 
Fusion proteins were developed for crystallization experiments. Protein complexes 
crystallize best when one partner is saturated, but the excess of the other partner required 
may inhibit crystallization. Fusion proteins create a saturated “complex” without any 
excess binding partner.  
Purifications proceeded according to the procedure outlined in Methods. A gel 
would be run following the Ni column on the first day to assess quality. Fractions 
containing few contaminating proteins and reasonable concentration would then be pooled. 
The concentration of protein was then measured (typical total protein between 30-60 mg 
per litre of culture used) and TEV protease was added. 
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The next and final check occurs after the final ion exchange column. 
 
    kDa   Mw 1    2   3    4    5 kDa Mw  1    2    3    4    5    6   7     8   9  10  11   12  13 14 
       
Figure 3.1 Fusion Protein Production a) Expression and solubility test for StrpII-PIP-
UBM1-PCNA protein, expressed with TEV-cleavable His-Mocr solubility and affinity tag. 
1) uninduced cell lysate. 2) induced cell lysate after 4h growth at 37 °C. 3) soluble fraction 
of 37 °C expression. 4) induced cell lysate after overnight growth at 16 °C. 5) soluble 
fraction of 16 °C expression. The expression and solubility are typical of the fusion 
proteins, save the little finger fusion proteins, which tend to be less soluble even after 
overnight low-temperature growth. b) TEV digestion and final ion exchange fractions for 
StrpII-PIP-36del-UBM1-PCNA fusion protein, an example of its type chosen because the 
contaminant band is easily seen. A low molecular weight (Mw) array is used as a reference 
standard with bands at 97.4, 66.2, 45, 31, 21.5, and 14.4 kDa. After successful TEV 
protease (31 kDa) digestion of the tagged protein at 66 kDa (lanes 1-2), the digestion 
product at 45 kDa was loaded on an anion exchange column (flowthrough in lane 3) and 
eluted (lanes 4-14). Early peak fractions (5-10) can be pooled to exclude the major 
contaminant at 40kDa. 
PCNA alone tends to run higher than expected from its molecular weight (see 
PCNA purification below), so it is not surprising that the fusion proteins do too. In this 
case, the 40 kDa StrpII-PIP-36del-UBM1-PCNA fusion appears to run the same as the 45 
kDa marker. The contaminant just below the main protein band is present in all fusion 
proteins and can be removed by only pooling early peak fractions with minimal 
contamination. It is not a degradation product; the pooled early fractions can be kept at 
Uncut Protein 
Fusion Protein 
Contaminant 
TEV Protease 
HisMocr Tag 
a      b 
97.4 
66.2 
45.0 
31.0 
21.5 
97.4 
66.2 
45.0 
31.0 
21.5 
14.4 
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room temperature for two weeks without any sign of degradation. PIP-UBM1-PCNA 
proteins can be concentrated to approximately 15mg/mL safely. 
The fusion proteins were not able to be ubiquitinated at K164 alone. Since site-
specific ubiquitination could not be achieved, the UBM had no binding partner and could 
not be anchored to a specific region. This may have been a factor in the failure of the 
crystallization trials. 
3.1.2 Short polι C-terminal proteins are stable, longer forms are more delicate 
 Polι C-terminal proteins were the model proteins of choice for studying all aspects 
of the interaction between polι and Ub-PCNA. PIP-UBM1 (aa415-530) is the workhorse 
protein; it is stable, easy to purify, contains both major interacting motifs, and has no 
internal deletions. It has been used for every experiment during this project. PIP-UBM1-
UBM2 (aa415-715) contains the entire C-terminal domain. It has been used for analytical 
ultracentrifugation experiments to determine whether the full-length protein behaves in the 
same manner as the truncated protein. PIP-UBM1-UBM2 more prone to aggregation than 
the PIP-UBM1 protein and cannot be concentrated to the same concentration (m/v). Its 
thermal stability is also poorer, but it does not have any significant effect at either 4 ºC or 
20 ºC.      
Purification of polι C-terminal proteins is straightforward and requires only two 
columns. For the first day, the Ni column only requires a spot test check to pool fractions 
and a Bradford assay to measure protein for TEV digestion (typical values are roughly 50-
100 mg per litre of cell culture). 
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           kDa Mw 1    2     3  Mw  1   2   3   4    5  6   7  8   9  10 11 12 13 14 
 
Figure 3.2 C-terminal protein production a) Expression and solubility test for PIP-UBM1 
protein, expressed with TEV-cleavable His-Mocr solubility and affinity tag. 1) uninduced 
cell lysate. 2) induced cell lysate after 4h growth at 37 °C. 3) soluble fraction of 37 °C 
expression. b) Example SDS-PAGE gel outlining purification of PIP-UBM1 C-terminal 
fragment as an example of this class of protein. After enrichment and purification of the 
target protein by Ni-affinity chromatography (lane 5), the final anion exchange step 
eliminates the bulk of the contaminants. The remaining weak contaminants are eliminated 
by size-exclusion chromatography. 
PIP-UBM1 proteins may be safely concentrated to 20 mg/mL but this is typically 
unnecessary; 10-15 mg/mL is a typical target concentration. The low molecular weight of 
the protein means that even this lower concentration has a high molarity. PIP-UBM1-
UBM2 proteins may be safely concentrated to 10 mg/mL. 
3.1.3 PCNA purification is highly effective 
 PCNA is the basis for the other major component of the complex being studied. It 
or Ub-PCNA has been used in all experiments in this investigation. Purification followed 
the procedure outlined in Methods. Each PCNA monomer is tagged with a TEV-cleavable 
8xHis tag. The protein forms a strong trimer, so the protein being purified may be treated 
as a single unit with 3 such tags. The protein strongly binds the first Ni column and may 
HisMocr- 
PIP-UBM1 
PIP-UBM1 
HisMocr 
a  b 
97.4 
66.2 
45.0 
31.0 
21.5 
14.4 
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be washed with high imidazole before elution and is pure after this first stage. Subsequent 
purification steps are largely to separate the cleaved tag and the TEV protease. 
 
kDa Mw  L  C FT  1    2   3   4   5   6   7    8    9   Mw Load        Elution Fractions 
 
Figure 3.3 PCNA Production a) SDS-PAGE gel demonstrating Ni-affinity 
chromatography of His-PCNA. The 8xHis tag confers powerful Ni affinity to PCNA, 
which permits stringent washing (lane 1) and elution (lane 2) of pure protein at the first 
step of the purification. After tag removal, the 2nd Ni column traps nearly all the 
contaminants, leaving pure PCNA in the second flowthrough fraction (lane 5). b) SDS-
PAGE gel of the final anion exchange step. Purity has not been improved between the load 
and elution fractions, but the protein is now in a more appropriate buffer without leached 
Ni and is contained in a smaller volume. The anion exchange chromatogram may also be 
used as a quality check. 
The final ion exchange column removes any nickel or imidazole that may still be 
in the protein buffer and concentrates the protein before the final centrifugal concentration. 
 PCNA may be concentrated to 20 mg/mL, but typically 12-15mg/mL was used 
since it must be diluted anyway during its ubiquitination reaction. Typical yield is 10-15 
mg per litre of culture used. The protein was dispensed into 5 mg aliquots for ease of use. 
Protein not immediately ubiquitinated was flash frozen and stored at -80 ºC. Frozen PCNA 
may be ubiquitinated immediately after thawing; refreshing is achieved during the 
ubiquitination protocol and the customary size-exclusion before the final use. 
a         b 
97.4 
66.2 
45.0 
31.0 
21.5 
14.4 
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3.1.4 Ubiquitin purification is high yield 
 Ubiquitin has been purified for the purpose of ubiquitinating PCNA. The ubiquitin 
purification follows an atypical protocol, and at no point does the target protein bind to a 
chromatography column. Anion exchange columns are used twice, but these only remove 
contaminants and the ubiquitin remains in the flowthrough fraction. This causes the volume 
of the buffer containing the protein to increase with each step. To accommodate the large 
final volume, a pressure-fed concentrator with a 40 mL capacity and a 5000 Da MWCO 
was used to concentrate the sample. The concentrator also had an internal magnetic stir bar 
to prevent overconcentration near the membrane. Even with this concentrator the flow rate 
was roughly 20 mL per hour. Once the total volume reached 10mL, the sample was 
transferred to a 15mL centrifugal concentrator to finish concentrating. hUb was 
concentrated to its working concentration of 18.6 mg/mL and had a final yield of 74.3 mg 
from 4 L of cell culture. 150 µL aliquots were made and flash frozen for later use. 
3.1.5 Ubiquitination reaction is high yield, scalable 
PCNA is ubiquitinated in 50 mL conical tubes, in the reaction buffer outlined 
above. The reaction buffer is then loaded on a Q column as outlined in Methods to isolate 
the Ub-PCNA. The excess ubiquitin and enzymes do not bind the column at the loading 
buffer’s ionic strength, and the Ub-PCNA that elutes from the column is pure. 
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          kDa   Mw   4     5     6     7     8      9 
 
Figure 3.4 Ubiquitination Products SDS-PAGE gel demonstrating the final state of Ub-
PCNA after anion exchange chromatography to remove the enzymes involved in the 
reaction. Each numbered lane represents the sequential 1.4 mL peak fraction collected from 
the Q column. The faint band below the strong Ub-PCNA band is the remaining PCNA. 
Ub-PCNA is effectively pure at this stage. 
Ub-PCNA can be concentrated to 20 mg/mL but is usually only concentrated to 
15mg/mL. The same mass of Ub-PCNA can be recovered as the mass of PCNA used in the 
reaction (~90% yield). 
3.2 Difficulties in crystallizing PIP-UBM1/Ub-PCNA complex 
 PIP-UBM1-PCNA fusion proteins were screened for crystals using the screens and 
experimental setups outlined in Materials and Methods. No protein crystals were observed 
nor any promising phase separations. Fusion proteins appeared to be more susceptible to 
aggregation compared to PIP-UBM1 + Ub-PCNA complexes of similar concentration, 
which suggested that the fusion proteins were less stable than the natural complex. Certain 
conditions (namely divalent cations, acidic pH, PEG range 4000-6000) tended to cause 
immediate heavy aggregations; screens which were biased toward these conditions were 
screened at lower concentrations initially then generally excluded from second-round 
screenings. 
Ub-PCNA 
PCNA 
97.4 
66.2 
45.0 
31.0 
21.5 
14.4 
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 Natural complex (PIP-UBM1 and Ub-PCNA) screening had been attempted by the 
laboratory before the beginning of this investigation, without success. After the completion 
of fusion protein trials, the focus returned to the natural complex. Before returning to 
crystallization trials, the natural complex was studied to challenge the assumptions that had 
been made about it, particularly the specificity of the ubiquitination reaction and the excess 
of PIP-UBM1 required to saturate the complex.  
3.3 The ubiquitination reaction is site-specific and monoubiquitination-specific 
 A possible reason for the failure of a crystallization trial would be a heterogeneity 
in the sample. In the case of the PIP-UBM1/Ub-PCNA complex, the most probable 
heterogeneity would be the presence of multiple ubiquitination sites. The SDS-PAGE gel 
of the ubiquitination product showed a single, strong band. Time-course experiments had 
never shown an intermediate product that would suggest that the product was 
polyubiquitinated, and a ubiquitination reaction that was oversupplied with ubiquitin and 
reacted for twice the normal time did not produce any bands higher than the normal 
product. These results demonstrated that the product of the ubiquitination reaction is 
exclusively mono-ubiquitinated PCNA. The literature on the reaction used (Hibbert and 
Sixma, 2012) had demonstrated that K164 was necessary for the reaction, but it did not 
conclusively prove that there were not multiple mutually-exclusive possible mono-
ubiquitination sites. 
3.3.1 K164R mutant PCNA abolishes ubiquitination 
 The specificity test using K/R point mutations that was performed by Hibbert and 
Sixma was extended to also investigate K168, which is the most likely off-target 
ubiquitination site (Hibbert and Sixma, 2012). PCNA of wild-type, K164R, K168R, and 
the K164/168R double mutant were purified for the experiment and then ubiquitination 
reactions for each were run simultaneously. The SDS-PAGE gel of the ubiquitination 
reactions is displayed below. 
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Figure 3.5 Ubiquitination Assay by Point Mutation SDS-PAGE gel of ubiquitination 
reaction for wild-type (WT) PCNA and three K/R PCNA mutants. Wild type PCNA is 
ubiquitinated as a control and the reaction ends in a single band. The K164R mutation 
abolishes the ubiquitination, leaving the PCNA band unchanged and no ubiquitinated 
products. K168R has little effect, with the majority of the PCNA being ubiquitinated in the 
same manner as wild type, suggesting that K168 is not a target of this reaction. The 
K164/168R mutation also abolishes ubiquitination, as expected after the results of the 
K164R mutation. These results strongly suggest that the reaction used is site-specific to 
K164. 
 The results of these ubiquitination reactions show that K168R can be ubiquitinated 
like wild-type PCNA, while K164R and K164/168R are unable to be ubiquitinated under 
the reaction conditions used. This suggests that K164 is the sole lysine ubiquitinated by the 
reaction. K168 may have a role in the reaction, since the K168R reaction did not go to 
completion, but it does not appear to be a ubiquitination target. These results suggest that 
the ubiquitination reaction is site-specific and that the products are homogenous. However, 
it was prudent to continue to confirm the homogeneity of the reaction products. 
3.3.2 Mass spectrometry experiments detect ubiquitination at K164 only 
 Identification of other possible ubiquitination sites was performed using in-gel 
digestion of Ub-PCNA followed by mass spectrometry (Parker et al., 2009). After 
Uba1 
Ub-PCNA 
PCNA 
UbC S22R 
Ub 
97.4 
66.2 
45.0 
31.0 
21.5 
14.4 
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digestion, peptide fragments of Ub-PCNA were identified by MALDI-TOF mass 
spectrometry.  
The following peptide fragments of PCNA were detected by mass spectrometry. The 
underlined peptide is the sole fragment found with the GG scar from ubiquitination. 
Table 3.1 Tryptic digest products of Ub-PCNA identified by MALDI-TOF. 
Mass (Da) Peptide from Sequence 
653.3 MFEAR 
754.4 YYLAPK 
778.3 IEDEEGS 
857.5 LVQGSILK 
871.4 VSDYEMK 
884.5 IADMGHLK 
894.4 MPSGEFAR 
932.5 YLNFFTK 
974.4 SEGFDTYR 
1261.6 CAGNEDIITLR (with carbamidomethyl adduct) 
1293.6 FSASGELGNGNIK 
1381.7 NLAMGVNLTSMSK (with oxidation) 
1615.9 ILKCAGNEDIITLR (with carbamidomethyl adduct) 
1984.0 DLSHIGDAVVISCAKDGVK (with GG scar) 
2075.0 AEDNADTLALVFEAPNQEK (with carbamidomethyl adduct) 
2424.3 ATPLSSTVTLSMSADVPLVVEYK (with oxidation) 
2665.3 DGVKFSASGELGNGNIKLSQTSNVDK 
3307.6 LSQTSNVDKEEEAVTIEMNEPVQLTFALR (with oxidation) 
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MFEARLVQGS ILKKVLEALK DLINEACWDI SSSGVNLQSM DSSHVSLVQL  
TLRSEGFDTY RCDRNLAMGV NLTSMSKILK CAGNEDIITL RAEDNADTLA  
LVFEAPNQEK VSDYEMKLMD LDVEQLGIPE QEYSCVVKMP SGEFARICRD  
LSHIGDAVVI SCAKDGVKFS ASGELGNGNI KLSQTSNVDK EEEAVTIEMN  
EPVQLTFALR YLNFFTKATP LSSTVTLSMS ADVPLVVEYK IADMGHLKYY  
LAPKIEDEEG S    
Figure 3.6 Coverage map of PCNA by MALDI-TOF fragments. Highlighted regions are 
those covered by the fragments detected by mass spectrometry. The red highlighted K 
residues are the three lysine residues not covered by the peptides. 
 These data show a single peptide containing a GG shift. This peptide contains two 
lysine residues: K164 and K168. It is unlikely that the K168 residue is the site of 
modification; the GG scar is expected to cause a missed cleavage at scarred residue and the 
cut site of the scarred fragment is at K168. It is also unlikely that there are ubiquitinations 
at the sites not detected. The sample was taken from a gel band containing solely 
monoubiquitinated PCNA, and there is no evidence of any unmodified K164. Furthermore, 
two of the unmapped lysines are on the internal pore of the PCNA trimer and are difficult 
to access for ubiquitination. 
The results of this experiment confirm that the ubiquitination reaction created 
mono-Ub-PCNA site-specific to K164 within the detection range of the mass spectrometry 
experiment. Heterogeneity of the Ub-PCNA sample is not a probable cause of the failure 
of the crystallization trials. 
3.4 SEC-MALS experiments demonstrate stability of 1:1 complex 
 Once crystallization trials were abandoned, other avenues of studying the structure 
of the complex were considered. SEC-MALS was considered as a starting point to 
characterize the complex ratio and the stability of the complex over time. A Ub-PCNA 
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trimer has binding sites to completely accommodate three PIP-UBM1 binding sites. Prior 
ITC studies have demonstrated that Ub-PCNA has good affinity for PIP-UBM1, with 
micromolar Kd. Size-exclusion chromatography experiments were able to separate the 
complex from unbound Ub-PCNA and PIP-UBM1. However, it has not been possible to 
distinguish between different ratios using the sizing column based on elution position, and 
the PIP-UBM1 protein has poor UV absorption which make it difficult to estimate the 
excess separated by the column. The combination of these factors may have contributed to 
an erroneous assumption that the PIP-UBM1/Ub-PCNA complex was reasonably saturated 
with a small excess of PIP-UBM1. 
Table 3.2 Table of theoretical molecular weights of PIP-UBM1 and Ub-PCNA complexes. 
Species 
PIP-
UBM1 
Ub-PCNA 
(trimer) 
1:1 Complex 1:2 Complex 1:3 Complex 
Theoretical 
MW (kDa) 
13.3 111.9 125.2 138.5 151.8 
 
SEC-MALS experiments were performed to determine whether a complete PIP-
UBM1 complex could be formed and determine whether the complex is stable enough to 
survive size-exclusion chromatography.  
 
42 
 
 
Sample Run Ub-PCNA 1:4.5 Ub-PCNA:PIP 1:9 Ub-PCNA:PIP 
Measured 
MW (kDa) 
108.86 ±0.81 118.14 ±0.8 118.31 ±0.97 
 
Figure 3.7 Multi-angle light scattering refractive index vs elution volume and chart 
showing measured molecular weight. The red peak has Ub-PCNA Alone, the yellow peak 
has 9:2 PIPUBM1:Ub-PCNA (trimer), and blue has: 9:1 PIPUBM1:Ub-PCNA (trimer). 
The 9:2 and 9:1 peaks have identical elution volumes and estimated molecular weight. 
 Good single peaks were observed for all complexes, well separated from the excess 
PIP-UBM1 peak further down. Complexes elute earlier than the Ub-PCNA alone; the shift 
is small but definite. The two complex ratios do not have a notable difference in the elution 
volume. 
 The mass estimation and complex ratio results were unexpected. Even at a Ub-
PCNA concentration of 7.7 µM and a 2:9 ratio of Ub-PCNA:PIP-UBM1, the largest stable 
complex that can be measured from the column is only a 1:1 Ub-PCNA(trimer):PIP. There 
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is no change in the observed weight even after doubling the ratio of ligand to trimer. Given 
that ITC experiments had determined the Kd of the interaction to be on the order of 5 µM, 
this was a great surprise and suggested that the assumed complex ratio may have been 
incorrect. 
3.5 Complex investigation using analytical ultracentrifugation 
The complex ratio observed in the SEC-MALS experiments did not match the prior 
expectations, so the next step was to characterize the complex in solution by a different 
method. Sedimentation velocity experiments were performed as outlined in Materials and 
Methods to estimate the molecular weight of the complexes present at varying ratios of 
PIP-UBM1 and Ub-PCNA. Once the range of possible complexes was determined, 
sedimentation equilibrium (AUC-SE) experiments were performed to determine the 
binding constants of the complex. 
3.5.1 Sedimentation velocity experiments observe a maximum complex ratio of 1:2 
 The first set of AUC-SV experiments were performed using PIP-UBM1 and Ub-
PCNA. PIP-UBM1 was the protein used to compare the results to those of the initial SEC-
MALS experiments that showed unexpected complex behaviour. 
Each experimental cell contained 2 mg/mL Ub-PCNA (18 µM trimer). Cells were 
set up with the following ratios of Ub-PCNA:PIP-UBM1: 1:0, 1:1, 1:3, 1:6, and 1:9. This 
concentration produced an absorbance value of 1 in the setup used, which gave a reliable 
signal with a small noise component. At the wavelength chosen (293 nm) PIP-UBM1 is 
nearly invisible (see Figure 3.8) but Ub-PCNA absorbance is still reasonably strong. 
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Figure 3.8 Absorbance spectrum of PIP-UBM1. 280nm is a standard UV wavelength for 
measuring the concentration of protein. This absorbance is primarily from aromatic 
residues (Phe, Tyr, Trp). Tryptophan has a larger aromatic system and permits the 
absorbance of longer wavelengths. PIP-UBM1 lacks tryptophan residues, and the 
absorbance spectrum above shows weak absorbance in the 290-300 nm region. 
The samples were mixed to 400 µL. The experiments were performed using 2-
sector cells. 380 µL of sample were loaded into the sample cell and 400 µL of Sizing Buffer 
was loaded into the corresponding reference cell. 
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Figure 3.9 AUC-SV of PIP-UBM1/UbPCNA complex a) full range of sedimentation 
coefficients observed in solution during Ub-PCNA-PIPUBM1 AUC-SV experiments. c(s) 
curves are normalized to the peak value. No significant impurities or additional species are 
observed. PIP-UBM1 is virtually invisible at the chosen wavelength by design, save the 
small peak at 1.5 s during the maximum concentration run (9:1 ratio, red curve). b) section 
of the data focusing on Ub-PCNA and complexes to better illustrate the shift of 
sedimentation coefficient as the ratio of Ub-PCNA:PIP-UBM1 increases. The single peak 
in each run suggests that multiple states are in equilibrium in each case and the interchange 
is much faster than the timecourse of the experiment. 
Table 3.3 Sedimentation coefficients and estimated molecular weights for PIP-UBM1/Ub-
PCNA complexes, with inferred complex ratio. 
Solution Ratio Sw MW (kDa) Complex Ratio Theoretical Mw 
1:0 5.0 115 1:0 111.9 
1:1 5.4 125 1:1 125.2 
1:3 5.5 130 1:1.5  
1:6 5.6 136 1:2 138.5 
1:9 5.7 137 1:2 138.5 
 
Sedimentation coefficients are listed as Sw after conversion to the theoretical 
sedimentation coefficient in water. The probable complex ratio of each sample was 
determined based on theoretical molecular weights for PIP-UBM1, Ub-PCNA, and their 
possible complexes. Refer to Table 3.2 for theoretical molecular weights of the component 
proteins and possible complexes. 
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These molecular weight estimates suggested that each Ub-PCNA trimer can bind 
two PIP-UBM1 partners, not the three that had been originally assumed. There was 
virtually zero shift between the mass estimation of the 1:6 and the 1:9 runs, which suggests 
that the complex is the upper limit on the complex ratio. The 1:1 peak is broad, which 
suggests that it is not a homogenous complex but rather a mixture of 1:0, 1:1, and 1:2 
complexes, with an average molecular weight corresponding to 1:1. This heterogeneity 
suggests that the two Kd values are close enough to be in equilibrium with one another. 
 One incidental finding is the excess of PIP-UBM1 required to saturate the Ub-
PCNA ring may have had an impact on crystallization experiments. Most crystallization 
trials had been performed with a ratio between 1:3 and 1:4.5 (trimer:PIP), but the results 
of this experiment suggest that the complex is not saturated in this condition. 
Crystallization experiments are most likely to succeed when performed using a 
homogeneous protein sample, and these AUC-SV experiments may have provided insight 
into the failure to crystallize the complex. 
 The main possible source of error in this experiment is the estimation of the 
molecular weight. The sedimentation values (s) are the direct product of the experiment. 
The molecular weight is estimated from this based on factors like partial specific density 
and the estimated shape of the particle. The molecular weight of Ub-PCNA was known 
and used to estimate the mass of the complexes. However, the shift in s is so small between 
complexes that the estimated molecular weights may have been incorrect and so the 
estimated complex ratio would be incorrect as well. 
3.5.2 AUC-SE experiments suggest that the first and second additions are of similar affinity 
and in equilibrium 
 Having determined the range of possible complexes by AUC-SV, further 
experiments were needed to measure the dissociation constant. Sedimentation equilibrium 
experiments were performed to determine the dissociation constants of the PIPUBM1/Ub-
PCNA complex. Complex stoichiometry and sedimentation coefficients were determined 
by sedimentation velocity experiments and used to inform the experimental design of the 
SE experiments. Once again, a wavelength of 293 nm was used to keep the PIP-UBM1 
nearly invisible and only track the position of Ub-PCNA and its complexes. A Ub-PCNA 
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concentration of 8.9 µM was chosen to achieve an absorbance of 0.4 AU when the cell is 
at rest. This is to balance the need for a high enough concentration for a reliable signal with 
the tendency for the absorbance at the bottom of the cell exceed the detector range. Prior 
ITC experiments had determined a Kd value near 5 µM, so the final concentration of 8.9 
µM is appropriate. Cells were run with ratios of 1:2 and 1:4 Ub-PCNA:PIP-UBM1, which 
were chosen based on the qualitative assessment of the AUC-SV c(s) distribution. The 
multi-speed equilibrium experiment was conducted using the following cell conditions and 
speed settings. 
Table 3.4 Speed/time settings for PIP-UBM1/Ub-PCNA AUC-SE experiment. 
Scan # Mean RCF (g) Hours between Scans Total Hours 
1 4,660 26 26 
2 4,660 4 30 
3 7,280 15 45 
4 7,280 4 49 
5 14,270 15 64 
6 14,270 4 68 
7 23,580 15 83 
8 23,580 4 87 
 
When setting a speed, a long period of time was left to allow for equilibration in the cell. 
A second scan was performed 4 hours later at each speed to confirm that equilibration had 
completed by overlaying scans. Each cell came to equilibrium successfully, but it was 
found that at the two highest speeds the proteins had sedimented too much and were not 
able to provide any useful data. Similar issues were found with the 4:1 cell. For that reason, 
they were excluded from analysis and the speeds chosen were adjusted for the PIP-UBM1-
UBM2 experiments. 
Data analysis was performed in SEDPHAT using the 3-site symmetric model, using 
the Ub-PCNA trimer as component A and PIP-UBM1 as component B. The sedimentation 
values of Ub-PCNA and the two observed complexes were given to the program, as was 
an extrapolated value for the hypothetical “saturated” complex. 
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Figure 3.10 Sedimentation equilibrium fit for PIP-UBM1/UbPCNA. Upper graph: 
absorbance vs radial length for 4,660 g (green) and 7,280 g (red). Lower graph: residuals 
of the fit. Data is cut off before the end of the cell as absorbance exceeds A=1. Overall fit 
is good, the residuals are not perfectly randomly distributed as might be hoped. 
Table 3.5 Dissociation constants for PIPUBM1/Ub-PCNA complex determined by 
sedimentation equilibrium. 
Kd1 Kd2  Kd3 χ2 
1.01 ± 0.36 µM 2.85 ± 1.22 µM >>Kd1 0.312 
 
 Dissociation constants were determined with a 95% confidence interval. These 
values agree with the qualitative observations of the sedimentation velocity experiment. 
Both experiments suggest that Ub-PCNA can host only two PIP-UBM1 binding partners 
despite containing 3 sets of binding sites. In this case, the Kd3 is so large that the program 
has effectively not observed any contribution and offered an absurdly large value as a 
placeholder. The two real Kd estimates are close enough that they are in equilibrium with 
one another, rather than sequential addition. This agrees with the peak broadening seen in 
the SV experiments. Finally, the real Kd estimates are both in the magnitude of the prior 
ITC experiments. 
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 Despite best efforts, it is possible that the shift in the s value is so small and the 3-
site binding model is so complex that these values represent an overfitting of the data. 
Sedimentation values from the AUC-SV experiment were used as a guide for the fit, 
possibly introducing an improper bias into the analysis. 
3.5.3 Sedimentation velocity experiments with PIP-UBM1-UBM2 show similar 1:2 
binding limit. 
 Sedimentation velocity experiments were then run using the larger PIP-UBM1-
UBM2 protein. PIP-UBM1 is a convenient protein of the polι C-terminal domain, but it is 
a small representative part of that larger domain. Since the ratio of complex using the small 
PIP-UBM1 fragment had been determined, the next step was to determine the complex size 
limit using the larger PIP-UBM1-UBM2 protein and whether the larger domain would face 
similar constraints. PIP-UBM1-UBM2 contains the entire suite of interacting motifs in the 
C-terminal domain; it would be more representative of the biologically relevant complex 
than the small fragment used in most experiments. Ub-PCNA was run alone as a reference 
standard at a concentration of 4.5 µM, and mixtures of Ub-PCNA:PIP-UBM1-UBM2 were 
run at ratios of 1:1 and 1:4. 
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Sample Ratio Sw MW (kDa) Complex Ratio Theoretical Mw 
1:0 5.0 115 1:0 111.9 
1:1 5.7 137 1:1 146 
1:4 6.5 158 1:2 180.1 
 
Figure 3.11 AUC-SV of PIP-UBM1-UBM2/Ub-PCNA complex Observed c(s) 
distribution of PIP-UBM1-UBM2 and Ub-PCNA mixtures, estimated molecular weights, 
and estimated stoichiometry of the observed complexes. As with the PIP-UBM1 AUC-SV 
experiment in figure 3.8, single intermediate peaks are observed as a result of rapid 
interchange at equilibrium. 
 The molecular weight estimates were not as accurate as the PIP-UBM1 results, but 
they were enough to interpret the data. The higher molecular weight estimate suggested 
that the complex was sedimenting faster than its actual molecular weight would suggest. 
This was unexpected since unstructured proteins are generally assumed to sediment more 
slowly than a structured globular protein. PIP-UBM1-UBM2 appeared to adopt a 
maximum 1:2 complex with Ub-PCNA. If the first addition binds ubiquitin moieties with 
both UBMs, the second addition can only bind with one of its two UBMs, which would 
make the second addition less stable. The 1:2 peak has not sharpened to match the Ub-
PCNA, suggesting that the complex has not fully saturated and may explain why the 
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molecular weight estimate is below the theoretical 1:2 weight. This also suggests that the 
second addition may be weaker than the second addition in PIP-UBM1. 
3.5.4 AUC-SE experiments with PIP-UBM1-UBM2 show similar binding pattern to PIP-
UBM1 
 Sedimentation equilibrium experiments were performed to determine the 
dissociation constants of the PIPUBM2-Ub-PCNA complex, again using the multi-speed 
equilibrium setup. The wavelength chosen for absorbance measurements was 280 nm, 
which was chosen to maximize sensitivity given there is not an available wavelength to 
observe Ub-PCNA but not PIP-UBM1-UBM2. The concentration of Ub-PCNA (2.7 µM) 
was again chosen to balance minimum and maximum absorbance. Ratios of 1:1 and 1:2 
Ub-PCNA:PIP-UBM1-UBM2 were run in two cells. 
Table 3.6 Speed/time settings for Ub-PCNA/PIP-UBM1-UBM2 AUC-SE experiment. 
Scan # Mean RCF (g) Hours Before Scan Total Hours 
1 4,660 26 26 
2 4,660 4 30 
3 7,280 15 45 
4 7,280 4 49 
5 10,480 15 64 
6 10,480 4 68 
 
 The scanning method was adjusted based on experience with the PIP-UBM1 
complex. The speed of the third scan was reduced to improve the data range and the fourth 
scan was omitted. Data processing was performed in the same manner as the PIP-UBM1 
complexes above. 
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Figure 3.12 Sedimentation equilibrium fit for PIP-UBM1-UBM2/UbPCNA. Upper graph: 
absorbance vs radial length for 4,660 g (blue), 7,280 g (yellow) and 10,480 g (red). Lower 
graph: residuals of the fit. Data is cut off before the end of the cell as absorbance exceeds 
A=1. Overall fit is good, the residuals are not perfectly randomly distributed as might be 
hoped, and the goodness of fit breaks down toward the bottom of the cell. 
Table 3.7 Dissociation constants for PIP-UBM1-UBM2/Ub-PCNA complex determined 
by sedimentation equilibrium. 
Kd1 Kd2  Kd3 χ2 
0.38± 0.04 µM 23.0± 1.32 µM >>Kd1 0.671 
 
 Dissociation constants were again determined with a 95% confidence interval. 
These Kd values for the PIP-UBM1-UBM2/Ub-PCNA are consistent with those found for 
PIP-UBM1. The overall pattern is similar, but they show higher affinity for Kd1, lower 
affinity for Kd2, and Kd3 is so large that the addition has not been observed. The decrease 
in Kd2 may be caused by increased crowding effects, but the difference between the Kd2 
values is so small that it may not reflect any actual difference. 
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3.6 Reprocessing of ITC data 
 Isothermal titration calorimetry experiments had been performed by the lab prior to 
this study. The experiment had assumed that each Ub-PCNA subunit would be able to host 
a PIP-UBM1 partner simultaneously, so the analysis considered the protomer Ub-PCNA 
as the binding partner of interest. 
 
Figure 3.13 Original ITC data analysis, against Ub-PCNA protomer. The n value is very 
nearly 1, and there is no reason to suspect that the maximum stoichiometry is anything but 
1:1 (equivalent to 1:3 Ub-PCNA (trimer):PIP-UBM1). 
This result appears to rest on incorrect assumptions, based on the AUC experiments, 
therefore it was prudent to reinterpret the data considering the new observation. Ub-PCNA 
concentration was reset to consider the trimer as the particle of interest, and the n value 
was set to float between 2.5 and 3.5 to represent the total number of available binding sites. 
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Figure 3.14 ITC isotherm for trimeric Ub-PCNA vs PIP-UBM1. The n value is nearly 3 
and does not show any indications that the Ub-PCNA is not being fully saturated by PIP-
UBM1. The approach to complete binding occurs between the mole ratio of 5-6, which is 
also the saturation point observed in the AUC-SV results. 
 ITC reprocessing does not show any signs that the Ub-PCNA trimer cannot be 
saturated by PIP-UBM1. The n value of 3.021 is a perfect match for complete saturation 
of the Ub-PCNA ring. It is possible that ITC cannot be used to determine the ratio of the 
complex. The Kd value 10 µM is a fair match for the AUC values (Kd = 1.01 and 2.85 µM). 
Considering that the ITC analysis is attempting to fit 3 identical binding sites, the 
underestimation of the Kd is unsurprising. Overall this experiment indicates that the AUC-
SV experiment is likely measuring the strength of the binding well. 
ITC has the fewest sources of error for investigating binding, so long as the protein 
concentrations are accurately measured. Its main shortcoming is that the software used to 
analyze it cannot separate sequential bindings. Rather than Kd1, Kd2, and Kd3, it returns a 
single Kd value and an n value for the binding ratio. 
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3.7 Solution structure study by small-Angle X-ray scattering 
 Small-angle X-ray scattering (SAXS) experiments were a good complement to the 
MALS and AUC experiments, and an opportunity to get structural information about the 
complex. A single set of experiments were able to provide both types of information. 
3.7.1 SAXS measurements of Ub-PCNA are in line with literature values, the 1:1 complex 
with PIP-UBM1 can be detected after SEC 
 Experimental runs were performed using Ub-PCNA alone, PIP-UBM1 alone, 3:1 
PIP:Trimer, and 2:1 PIP:Trimer. In mixtures containing Ub-PCNA, its concentration was 
5.3 mg/mL (47 µM) and PIPUBM1 was added to achieve the ratio required. PIP-UBM1 
alone was run at a concentration of 11.6 mg/mL (872 µM) to maximize scattering of the 
small protein. 
Table 3.8 Sample injection conditions for SEC-SAXS experiments. 
Injection Number 1 2 3 4 
Ub-PCNA Trimer (µM) 47.4 47.4 0 47.4 
PIP-UBM1 (µM) 0 142.8 872.2 97.7 
Injection Size (µL) 250 250 250 250 
Ratio Trimer:PIPUBM1 1:0 3:1 0:1 2:1 
 
 Data were collected as a series of images and initial data processing was performed 
using the RAW analysis suite, followed by ab initio modelling using DAMMIN, 
DAMMIF, and GASBOR. 
Basic SAXS processing was performed at the beamline using the RAW suite. 
Molecular weight (MW) and radius of gyration (Rg) measurements are easily processed 
and were used to assess the data quality. Ub-PCNA and the complex were both of good 
quality: each had higher molecular weights than theoretical but within the acceptable range 
for the experiment, and each had consistent Rg across the peak. These suggest that the 
sample quality was good and that the sample was monodisperse across the peak. PIP-
UBM1 alone did not scatter well enough to measure Rg but its molecular weight was 
consistent with the theoretical. 
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The following molecular weights and Rg values were measured during each run. 
Also included is the Dmax estimate. Dmax is a user-generated parameter and represents the 
longest linear dimension of the particle. Rg and Dmax values for Ub-PCNA are in line with 
values previously reported (Hibbert and Sixma, 2012). 
Table 3.9 Basic SAXS measurements for Ub-PCNA, PIP-UBM1, and complex.  
Sample Mw (kDa) Theoretical Mw Rg Dmax (Å) 
Ub-PCNA 118 111.9 39.9 127 
PIP-UBM1 13.7 13.3 N/A N/A 
1:1 Complex 138 125.2 44.5 157 
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Figure 3.15 Ub-PCNA and Complex SAXS comparison (a) Pair distance distribution 
functions (PDDF) and (b) plotted I(q) vs q (intensity vs scattering angle) for Ub-PCNA 
alone and PIP-UBM1/Ub-PCNA complexes. Ub-PCNA: red and blue curves. Complex: 
purple and green. These demonstrate that there is a measurable difference between the Ub-
PCNA and the complex. The PDDF graph shows that the complex is a physically larger 
particle, with a larger Dmax and larger average dimensions. The PDDF is also of 
approximately the correct shape. PCNA itself is ring shaped, while the ubiquitin moieties 
are placed at the outer edge and all face towards one of the faces. The overall shape of each 
plot is intermediate between the disc pattern and the sphere pattern, which is consistent 
with the structure of the molecule. The I(q) plot shows that the proteins are in good shape, 
and again has an observable difference between the complex and the Ub-PCNA alone. 
3.7.2 SAXS envelope modelling can reconstruct Ub-PCNA, reconstruction of the complex 
is ambiguous 
 Ab initio structure modelling of Ub-PCNA and the complex was performed to 
create a model of the shape of the Ub-PCNA alone and the complex. DAMMIF/N and 
GASBOR were both tested before GASBOR was chosen. DAMMIF/N’s dummy atom 
modelling had difficulty generating a pore to locate the PCNA ring. Averaging and 
a 
 
 
 
b 
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clustering also showed that the reconstruction was ambiguous and many possible models 
could fit the data. GASBOR’s dummy residue model created more interpretable envelopes 
and produced particularly good Ub-PCNA envelopes. 
 
Figure 3.16 Reconstructed model of Ub-PCNA using GASBOR dummy residue 
modelling. This model is looking toward Ub-PCNA’s rear face, with the plane of the ring 
parallel with the page, and the ubiquitin domains pointing toward the reader. 
This is a good reconstruction of Ub-PCNA in solution from low-resolution data. 
The PCNA pore is apparent, the pseudo-P6 symmetry of the PCNA ring looks to be in 
place, and the ubiquitin domains are placed in a semi-extended position. This 
reconstruction was achieved by enforcing P3 symmetry on the model. Unfortunately, this 
strategy cannot be applied to the complex reconstruction. 
PCNA 
Ubiquitin 
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Figure 3.17 Reconstructed model of PIP-UBM1/Ub-PCNA 1:1 complex using GASBOR 
dummy residue modelling. Left image shows the PCNA ring in plane of the page, right 
image shows the PCNA ring perpendicular to the plane. PIP-UBM1 is believed to appear 
as the bulge on the right in image A and above on image B. 
 The complex is only expected to have one PIP-UBM1 based on the observed 
molecular weight, so the symmetry of the complex is P1. This leaves the modelling 
program with fewer constraints. The reconstructions of the complex did not average or 
cluster well, which suggests that the data may be ambiguous, and the complex 
reconstruction is a best guess. Tentatively, the reconstruction appears to be in a trans- 
arrangement, with a wide, distributed mass of PIP-UBM1 along a side of Ub-PCNA. The 
cis- arrangement would be expected to be a narrow, clustered mass. This trans- 
arrangement may be a reason for the limited complex ratio observed in sedimentation 
velocity experiments. 
  
Ub-PCNA PIP-UBM1 
PIP-UBM1 
    a          b 
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4 Discussion 
4.1 The observed complex ratio between Ub-PCNA and polι is limited to two polι 
for each Ub-PCNA ring 
 At the beginning of this research project, the operating assumption that the complex 
between PIP-UBM1 and Ub-PCNA was straightforward: each Ub-PCNA protomer could 
host a single PIP-UBM1. Each PIP-UBM1 had a pair of binding motifs which bound to the 
complementary pair of binding sites on Ub-PCNA. We assumed that PIP-UBM1 was small 
enough (117aa) to be accommodated in multiple bindings on Ub-PCNA. 
 The initial SEC-MALS findings, with its hard cap of a 1:1 complex, were not 
expected but inconclusive. Even a large excess of PIP-UBM1 was not able to increase the 
measured molecular weight of the complex. The similar SEC-SAXS experiment confirmed 
the observation, but both shared the SEC component of the experimental setup. This system 
had the advantage of separating the complex from the excess binding partner. It was 
therefore possible that the 2nd and 3rd bindings were simply being shorn off as it flowed 
through the column. The difference in the speeds of the columns and the temperature during 
the columns may have contributed to the different MW estimates. To prove that the 
observed complex ratio was not an experimental artifact, another type of experiment had 
to be conducted. 
 Sedimentation velocity experiments were a perfect complement to the previous 
experiments. Like SEC-MALS and SEC-SAXS it provided a good estimate of molecular 
weight, but it did so with a completely different experimental method (sedimentation 
velocity vs. light scattering). This method also keeps the complex in question surrounded 
by the excess binding partner. Rather than stripping away excess protein, the complex 
sediments through a sea of excess protein and should maintain its state through the entire 
experiment. These experiments broadly agreed with the scattering experiments in that a 1:1 
complex forms readily but differed in demonstrating that a 2:1 complex is achievable with 
enough excess PIP-UBM1. The second addition is likely present in some proportion of the 
population in the “1:1” experiment, along with an equal proportion of free Ub-PCNA. This 
heterogeneity would be a hindrance to further crystallization experiments. 
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 Polι has moderately strong affinity for Ub-PCNA, as measured by ITC experiments. 
In both ITC and AUC experiments using PIP-UBM1 and Ub-PCNA, the complex appears 
to reach its final state at a ratio between 1:4 and 1:6. The apparent limit may be caused by 
the weak, dynamic binding, but the ease with which the first two additions occur suggests 
there may be a crowding factor that could be confirmed by structural studies. 
4.2 Comparison of methods to investigate binding behaviour  
 Analytical ultracentrifugation and isothermal titration calorimetry were used to 
investigate the binding of the complex. Sedimentation velocity experiments measured the 
molecular weight of the complex to determine the complex ratio, followed by equilibrium 
experiments to determine the dissociation constants. This method was chosen to observe 
the complex in solution with a large excess of its binding partners, unlike experiments that 
relied on a size exclusion column. Sedimentation equilibrium experiments were also able 
to determine each Kd separately and use those to make inferences about cooperativity in 
the binding. 
 Isothermal titration calorimetry experiments were used primarily for the 
determination of a dissociation constant. The n value was also used as an indicator of the 
complex ratio. ITC returns a single Kd, which represents an average of the three separate 
bindings. 
 ITC is a much simpler method, with fewer sources of error than the AUC 
experiments. Fitting a binding curve to the data has fewer degrees of freedom. Determining 
the dissociation constants by AUC in a three-site system has more degrees of freedom and 
therefore it can be difficult to conclude that the determined Kd values are accurate. Adding 
to this complexity, the data analysis requires determination of sedimentation and 
absorbance values for participating species, which introduces numerous possible sources 
of error. The sedimentation coefficients themselves are a possible source of error. Even if 
AUC-SV experiments determine accurate sedimentation coefficients, they must be 
converted to a molecular weight to be intelligible. Since the shift in mass is so small (each 
PIP-UBM1 added is only 11% of the mass of Ub-PCNA) it is possible that a small error in 
the mass calculation may lead to a misidentification of the complex observed. These errors 
combined make the AUC results less conclusive, so the disagreement of the n value from 
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ITC and the complex ratio found in AUC is troubling. It may be wise to take the AUC 
results as provisional at best, but it would be useful to consider their implications if they 
are borne out by further experiments. 
4.3 Complex structure predictions 
 Explicit structure determination by crystallographic and SAXS methods may have 
failed, but some predictions of the structure may be made. Ub-PCNA appears to be able to 
accommodate a maximum of two polι based on AUC experiments. Although both additions 
are in equilibrium with one another, SEC-MALS data suggests that the single-binding 
arrangement is the most stable over long time courses. Combined with the unobserved third 
binding, this suggests that there is a crowding effect that affects each subsequent binding. 
This crowding is suggestive of a trans-binding arrangement. A cis-binding arrangement is 
not necessarily immune to crowding effects, but the trans arrangements is virtually certain 
to cause this effect. 
 A definitive reconstruction of the SAXS envelope of the complex was not possible, 
but the best reconstructions tended to have broad regions assigned to the PIP-UBM1 
section. This may indicate that the complex is in dynamic equilibrium during the SEC-
SAXS experiment. Based on AUC-SV experiments, the apparent 1:1 complex may be an 
n equilibrium between the 1:0, 1:1, and 1:2 species. The SEC-SAXS method is normally 
employed to isolate species and capture scattering from a homogenous sample. In this case, 
a “1:1” sample may have quickly reached a new equilibrium state that could not be further 
isolated by the size exclusion column. 
 The polι/Ub-PCNA complex studied here may not be entirely biologically relevant. 
The TLS complex also includes Rev1 as a scaffold protein, and ubiquitinated polη is 
necessary for polι recruitment (Vaisman and Woodgate, 2017). It is possible that one or 
both UBMs may prefer to bind to other ubiquitinated proteins in the complex in vivo. Polι’s 
direct interaction with Ub-PCNA is still a matter of interest, as no structure of any Y-family 
C-terminal domain in complex has been solved. Models for TLS function rely on inferences 
from function experiments and molecular simulations. Solving the polι/Ub-PCNA complex 
would be an important part of modelling the overall TLS complex. 
63 
 
4.4 Implications for TLS mechanism and polymerase selection 
 The observation that truncated polι proteins cannot form a 1:3 complex with 
trimeric Ub-PCNA suggests that it is a poor candidate to participate in tool belts. The tool-
belt model of lesion bypass requires Ub-PCNA to host several TLS polymerases, each of 
which may probe the lesion. This increases the probability that the most efficient, and 
therefore likely the most suitable, polymerase performs the bypass. Tool-belts have been 
formed in vitro using PIP-containing proteins and a two-part tool belt of polη and Rev1 has 
been observed in yeast in vivo (Boehm et al., 2016). Y-family polymerases, which are the 
primary TLS polymerases, all have large, unstructured C-terminal domains that bind to Ub-
PCNA. 
 There is variation in C-terminal organizations between the Y-family polymerases 
(Figure 1.1). Polι cannot easily form tool belts even as the only available polymerase, 
where all three hypothetical proteins would be able to adopt the same arrangement to 
minimize crowding effects. It therefore seems unlikely that it would readily form tool belts 
alongside differently organized proteins like other members of the Y-family. 
While this finding does not exclude the possibility of tool belts within TLS, it 
demonstrates that polι is not suited to participating in them. If the tool-belt model is 
validated in humans and the other TLS polymerases form functional tool-belts in vivo, then 
that suggests that polι acts as a last-resort option. Polymerase ubiquitination (as outlined in 
the polymerase switch model) would also be at work in a tool-belt system. A lesion for 
which none of the tool-belt polymerases are suited would continue to stall replication. The 
first-response tool-belt polymerases would then continue to bind, probe, and be deactivated 
by ubiquitination. Eventually the local pool of these polymerases would deplete until their 
local concentrations dropped to the point that tool-belt formation could not continue, at 
which point polι would be able to bind Ub-PCNA and engage the lesion. Polι’s role in this 
model would be that of a last-line lesion specialist. Since it would only be activated rarely, 
this model would account for polι’s apparent low importance to organism survival; polι 
knockout mice being apparently healthy unlike XPV patients (Kanao et al., 2015). 
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Appendices 
Appendix A: Purification of Ubiquitination Enzymes 
hUba1 Purification 
 hUba1 purification followed the procedure outlined in Methods. As a ubiquitination 
enzyme, small quantities are needed, so doing a large scale (2 litre culture) purification can 
produce enough to ubiquitinate < 100 mg of PCNA. 
 
Figure A1 SDS-PAGE gel outlining Ni-affinity and anion exchange steps in Uba1 
purification. Strong contaminants remain. 
 Purity is not crucial for this protein, but it is still unacceptable at this stage. Protein 
was concentrated to 1mL and run on S200 to clean it up. 
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Figure A2 Final S200 fractions of Uba1. Acceptable purity has been achieved at this stage. 
 Peak fractions containing Uba1 were pooled and concentrated to 3.8 mg/mL (32 
µM). The protein was distributed in 30 µL aliquots, flash frozen, and stored at -80 ºC until 
used in ubiquitination reactions. 
hUbC S22R Purification 
hUbc S22R purification followed the procedure outlined in Methods. As a 
ubiquitination enzyme, small quantities are needed, so doing a large scale (2 litre culture) 
purification can produce enough to last a long time. The purification only requires two Ni 
columns, one after lysis and one after tag cleavage. 
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Figure A3 SDS-PAGE gel demonstrating the purification of UbC. High purity is achieved 
after the second Ni-affinity step that follows tag cleavage. 
 Since the protein is to be frozen and then only used in small quantities for a single 
preparative reaction, the small amount of Ni which leached from the column is acceptable. 
FT2 and FT3 were pooled and concentrated to 17 mg/mL (1 mM) with a yield of 51 mg. 
The concentrated protein was distributed into 200 µL aliquots and frozen down for later 
use. 
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